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Foreword
Every year, pharmacists provide more than 14 million face-to-face contacts with drug users. They play an important role in
their treatment and care, including dispensing drugs as part of supervised consumption arrangements and offering needle
exchange services. 
However, as highlighted by the Audit Commission’s report Changing habits, “…research has shown that many [pharmacists]
are an underused point of contact for the drug misusing population and would benefit from a closer relationship with
prescribing services and improved training.”
Following the memorandum of understanding between the National Treatment Agency for Substance Misuse (NTA) and the
Royal Pharmaceutical Society of Great Britain (RPSGB), this document was developed with the aim of providing guidance
for commissioning of pharmaceutical services for drug users. 
The introduction of the new pharmacy contract, as well as new approaches to prescribing and supplying medication,
requires close co-operation between professionals, particularly doctors, drugs workers and pharmacists, and a need to
develop positive partnerships with service users. Supplementary prescribing is a prime example of how flexible approaches
to the delivery of care and new professional roles can contribute to providing quality services to drug users. Plans are in
place for enhanced roles for pharmacists working in substance misuse, as pharmacists with a special interest and
consultant pharmacists. Advanced training programmes for pharmacists and pharmacy technicians through; for example,
the Centre for Pharmacy Postgraduate Education and the Royal College of General Practitioners, are ensuring we have a 
well-trained pharmacy workforce. The valuable role of pharmacists and technicians working in secondary care services and
specialist substance misuse teams should also not be forgotten.
It is early days for many of these new developments and the introduction of new ways of working presents many
challenges. This briefing offers best practice guidance for commissioners and providers on the development of service
specifications for pharmacists providing services to drug users, and helps providers, service users and commissioners 
to consider the benefits available and plan to make any developments safe and sustainable.
Paul Hayes
Chief executive, National Treatment Agency
3
Best practice guidance for commissioners and providers of pharmaceutical services for drug users 
Purpose of the guidance
This briefing offers best practice guidance for
commissioners and providers on the development of
service specifications for pharmacists providing services 
to drug users. It is subdivided into the following sections:
1. Executive summary – this provides a brief summary 
of each of the sub-sections in the main part of the
document and provides a rapid overview of the 
service specification.
2. Detailed sample service specifications – pharmaceutical
services to drug users.
Each section is subdivided, where relevant, into:
• Pharmacy-based needle exchange and harm reduction
• Dispensing and supervised consumption of substitute
medications by pharmacists involved in shared care
3. Clarifying current and future roles for pharmacists in the
provision of services to substance users. This section
briefly describes additional services that pharmacists and
their staff can, and do, provide for drug (and alcohol) users
4. Sample schedules.
Appendix 1: How community pharmacies are paid
Appendix 2: Understanding the new pharmacy contract
Appendix 3: NHS community pharmacy contractual
framework enhanced service – needle and syringe exchange
Appendix 4: NHS community pharmacy contractual
framework enhanced service – supervised administration
(consumption of prescribed medicines)
Appendix 5: NHS community pharmacy contractual
framework enhanced service – supplementary prescribing
by pharmacists
Appendix 6: Abbreviations used in this document.
Drug and alcohol misuse
The primary focus of Models of care: Update 2005 (NTA,
2005), and the service specifications described here, is adult
drug misuse treatment including harm reduction initiatives.
This guidance concentrates on the provision of:
• clean injecting equipment and advice on safer injecting
as part of a needle and syringe exchange programme 
• dispensing, supervised consumption of oral prescribed
drugs such as methadone and buprenorphine and shared
care services to drug users.
However, it is important for commissioners to recognise 
the wide range of services available from pharmacists 
and community pharmacies and the applicability of these 
service specifications to alcohol treatment services. 
Section 3 of this guidance looks at the differing roles and
services that pharmacists can and do provide to drug
(and alcohol) users.
4
Best practice guidance for commissioners and providers of pharmaceutical services for drug users 
The Royal Pharmaceutical Society
of Great Britain
The Royal Pharmaceutical Society of Great Britain (RPSGB)
is the professional and regulatory body for pharmacists in
England, Scotland and Wales. It also regulates pharmacy
technicians on a voluntary basis, which is expected to
become statutory under anticipated legislation. The primary
objectives of the society are to lead, regulate, develop and
represent the profession of pharmacy.
Key responsibilities of pharmacists
The RPSGB specifies a code of ethics and standards, to which
all pharmacists (and pharmacy technicians) must comply. 
In addition, the society publishes practice guidance, which
includes guidance for pharmacists on needle and syringe
exchange schemes and instalment dispensing services to drug
users. More recently, the RPSGB has published the Clinical
governance framework for pharmacist prescribers and
organisations commissioning or participating in pharmacist
prescribing (GB wide). From 1 January 2005, there is a
professional requirement for all pharmacists to put in place and
operate written standard operating procedures within individual
pharmacies to cover the dispensing process. Quite simply, a
standard operating procedure specifies in writing what should
be done, when, where and by whom. In addition, the new NHS
community pharmacy contract requires pharmacies to have
standard operating procedures in place for locally
commissioned enhanced services, including needle exchange
and supervised consumption of prescribed medication.
The National Treatment Agency
The National Treatment Agency for Substance Misuse (NTA)
is a special health authority within the NHS, established by
Government in 2001, to improve the availability, capacity
and effectiveness of treatment for drug misuse in England.
Treatment can reduce the harm caused by drug misuse to
individuals’ well-being, to public health and to community
safety. The Home Office estimates that there are
approximately 250,000 – 300,000 problematic drug
misusers in England who require treatment.
The NTA is responsible for meeting the Department of
Health’s (DH) targets to:
• double the number of people in effective, well-managed
treatment between 1998 and 2008
• increase the percentage of those successfully completing
or appropriately continuing treatment year on year.
The Pharmaceutical Services
Negotiating Committee
The Pharmaceutical Services Negotiating Committee
(PSNC) is recognised by the Secretary of State for Health as
representative of community pharmacy (in England and
Wales) on NHS matters. Much of the PSNC’s work involves
discussion and negotiation with the Department of Health.
The Pharmacy Misuse 
Advisory Group
The Pharmacy Misuse Advisory Group (PharMAG)
enables pharmacists with a professional interest in
substance misuse to share their expertise and aims to
raise the profile of pharmacists working in the field of
substance misuse, both within the profession and at
national and international  level. PharMAG aims to
encourage high-quality pharmaceutical care in this field,
acting as a source of information and responds to
national and local policy issues. 
Membership of PharMAG is open to all pharmacists 
and other professionals with an interest in optimising 
the pharmaceutical care of drug misusers. Current
membership includes pharmacists from community,
hospital, primary care, industry, prison service and
academic braches of the profession. The group publishes a
quartlerly magazine, PharMAGazine, sent to all members.
Further information and membership application forms can
be obtained from the chairman, Kay Roberts by email
kay@mymbrob.freeserve.co.uk or by phone 0141 337 6799.
This document is based on policy for England but the
principles are applicable to other UK countries.
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1 Executive summary
1.1  Definition of the service
There are a wide range of pharmaceutical services which
many pharmacists can and do provide. Commissioners
should work with pharmacists in the community, hospitals,
local pharmaceutical committees (LPCs), primary care trusts
(PCTs) and primary care organisations (PCOs), to ensure
there is widespread provision of a broad range of
pharmaceutical services available for drug users. Section 3
of this guidance describes the different roles and
responsibilities of pharmacists working in the various
sections of the NHS, as well as detailing the differing levels
of expertise attained by pharmacists.
This guidance concentrates mainly on provision of needle
exchange and supervised consumption of prescribed
medicines. These form part of the enhanced services tier of
the new community pharmacy contract. (Appendix 3 and
Appendix 4 detail the NHS enhanced service specifications
for these services – published September 2005). These
enhanced services are locally commissioned by PCTs and
PCOs. Appendix 1: How community pharmacies are paid
and Appendix 2 Understanding the new pharmacy contract,
provide more information and NTA guidance on local
enhanced and national enhanced services.
Where pharmacists have undertaken specific training and
attained the required level of expertise and competence,
they may be able to offer additional enhanced services to
clients such as supplementary prescribing (Appendix 5 –
published September 2005) that further support the NTA’s
treatment effectiveness strategy, to promote progression
through the treatment system for all individuals. At the time
of writing, the law has only recently been changed to allow
supplementary prescribers to prescribe controlled drugs. 
As a result, it has not been possible to include detailed
guidance for commissioners or providers on supplementary
prescribing by pharmacists. However, commissioners and
providers should refer to the RPSGB publication Clinical
governance framework for pharmacist prescribers and
organisations commissioning or participating in pharmacist
prescribing (GB-wide) (RPSGB, 2005).
A number of pharmacists who have completed the Part 2
Royal College of General Practitioners (RCGP) certificate in
the management of drug misuse have now also completed
supplementary prescribing training. Commissioners are
advised to contact local pharmacists who have completed
these courses with a view to investigating the potential for
commissioning pharmacists as supplementary prescribers.
1.2  Aims and objectives of the services
The overall aims of pharmacy services to drug users 
are to assist the service user to remain healthy, reduce
drug-related harm, provide service users with regular
contact with a healthcare professional and help them
access further advice or assistance.
Pharmacy needle exchanges aim to reduce the rate of
sharing and other high-risk injecting behaviours by providing
sterile injecting equipment and other support, as well as
ensuring the safe disposal of used injecting equipment.
Pharmacies providing dispensing services aim to ensure
compliance with the agreed treatment plan, improve
retention in drug treatment by providing instalment
dispensing and ensuring each supervised dose is correctly
administered to the patient for whom it was intended. 
They contribute to the shared care of the patient by liaising
with the prescriber or named keyworker directly involved 
in the care of the patient. They reduce the risk to local
communities of diversion of prescribed medicines onto 
the illicit drugs market.
1.3  Service user group served
Pharmacy needle exchange facilities are available to all
adult injectors who are using drugs illicitly. Where possible,
needle exchange and harm reduction facilities should also
provide interventions relevant to non-injectors.
Community-based dispensing, supervised consumption
and shared care are available to all individuals, in receipt of
an NHS prescription, who have drug-related problems,
including dependent opioid users as well as those who
present with additional polydrug use or concurrent use of
benzodiazepines, psychostimulants and alcohol.
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1.4  Contraindications and exclusions
Models of care: Update 2005 (NTA, 2005) focuses on the
commissioning of services for adults (those aged 18 years
or over). A person aged 17 years or under will normally
access a young person’s service. It is likely that the young
person will remain with the same pharmacy or pharmacist
after transferring to the adult service.
The pharmacist will not dispense a controlled drug
prescription if it does not fully comply with legal 
requirements. Dispensing and supply can be refused, 
in certain circumstances as defined by the new 
pharmacy contract.
1.5  Referral pathways
Access to pharmacy needle exchange facilities and harm
reduction initiatives is voluntary and open. Referrals are
accepted from a wide variety of sources, with self referral
being the most usual route of access, Whenever possible
and where appropriate, pharmacy service providers should
facilitate onward referral to specialist drug treatment services.
Access to treatment in a pharmacy is voluntary. Patients
have the right to choose which pharmacy they take their
prescription to be dispensed.
Commissioners and providers must work together to
ensure the overall capacity of the local dispensing system
is sufficient to meet the combined demand from all the
various prescribing services.
1.6  Basic assessment and ongoing harm
reduction advice and support
Pharmacists or other appropriately trained pharmacy staff
should provide direct input wherever possible to promote
harm reduction. Interventions should include a clear health
promotion element.
1.7  Care planning
A care plan for clients of pharmacy needle exchange
facilities is not required. Pharmacy staff should reinforce
the harm minimisation message and encourage hepatitis 
B immunisation and course completion.
All patients who are prescribed treatment should have written 
and structured care plans resulting from assessment, 
prior to prescribing. Providers should work with
prescribers, keyworkers and care co-ordinators to ensure
the name of the patient’s chosen pharmacy is included in
the prescriber’s care plan and the pharmacist should liaise 
with the multidisciplinary team on a regular basis.
Commissioners should ensure shared care arrangements
continue to include the pharmacist as the patient moves
between different prescribing services.
1.8  Co-ordination of care
Pharmacists will support the keyworker responsible for 
co-ordinating the patient’s care by monitoring continuity 
of care and contributing to the aim of maximising retention
of patients in the treatment system.
1.9  Description of services, care and
interventions provided
Pharmacists should be involved in strategic and operational
planning of services to drug (and alcohol) users, through the
inclusion of specialist pharmacy representation on drug (and
alcohol) action teams and shared care monitoring groups.
Pharmacy needle exchanges provide (but are not limited to)
screening, risk assessment, referral, advice and appropriate
needle exchange equipment.
In addition to supervised consumption and shared care,
pharmacy dispensing services provide (but are not limited
to) screening, risk assessment, referral, advice, and
compliance with legal and professional responsibilities.
1.10  Competencies and training
Health and safety training must be provided to staff,
including training on the handling of injecting equipment.
Pharmacists are encouraged to complete the two open
learning modules, Substance misuse and opiate treatment:
supporting pharmacists for improved patient care, provided
by the Centre for Pharmacy Postgraduate Education (CPPE)
in England, or the equivalent Scottish, Welsh, or Northern
Ireland packs. Pharmacists who have completed the Part 2
Royal College of General Practitioners Certificate (RCGP) in
the Management of Drug Misuse in Primary Care may be
eligible, in future, to apply for posts as pharmacists with
special interest (PhwSI) in drug misuse.
In addition, the National Pharmacy Association (NPA)
provides its members with a resource manual on operating
a pharmacy needle exchange, as do some multiple
pharmacy chains.
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1.11  Service principles
Pharmacy needle exchange facilities and harm reduction
initiatives provide an easy, low-threshold, open access and
user-friendly service.
The pharmacist ensures that supervised consumption 
takes place in a private or quiet area of the pharmacy.
Participating pharmacists have effective links with
prescribing services (including GPs) and provide advice 
and shared care where required. Pharmacists liaise with
services (including GPs) about specific patients and
prescribing regimens. The pharmacist shares relevant
information with all professionals involved in the treatment,
within the bounds of pharmacists’ professional
confidentiality guidelines.
Pharmacists are provided with support (for example, 
from a dedicated scheme co-ordinator) to operate needle
exchange, shared care and supervised consumption
schemes and there is pharmaceutical representation on 
the local shared care monitoring group.
1.12  Policies, protocols and written strategies
All pharmacists will have standard operating procedures
(SOPs) in place specific to their individual premises.
Pharmacy service providers will ensure information is
available enabling locum pharmacists to continue to provide
the commissioned services.
1.13  Monitoring and review
The manner in which monitoring and review are undertaken
may vary from area to area. In some areas, the local PCT,
PCO or DAT may develop and agree milestones and
targets, whereas in others these may be agreed by the local
pharmaceutical committee on behalf of all the pharmacy
contractors in the area.
1.14  Data collection and claims for payment
Data collection should be standardised to ensure uniformity
across the schemes. The task force to review services for
drug misusers, (Department of Health, 1996) recommended
a number of key performance indicators for pharmacies,
and (pharmacy) needle and syringe exchange schemes.
Robust payment arrangements for participating pharmacies
must be agreed locally. (See also Appendix 1: How
community pharmacies are paid, section 4.6.)
There must also be clear information on how to contact
scheme co-ordinators and what support and resources the
pharmacy can expect from scheme co-ordinators.
1.14.1 Payments to community pharmacies
Under the new pharmacy contract (see Appendix 2), the
enhanced services are locally commissioned by PCTs and
PCOs in response to local health needs. Services can be
based on nationally produced service specifications or
locally designed and negotiated with local pharmaceutical
committees (LPCs) at a local level.
Work has been ongoing to seek to agree benchmark prices,
but after meetings between the PSNC, NHS Confederation
and Department of Health, it appears that a better approach
is the publication of a pricing toolkit. At the time of writing,
the PSNC is developing a jointly agreed toolkit for pricing,
which will identify the elements to be considered in pricing
the service at a local level. It is envisaged these toolkits will
be available on the PSNC website at www.psnc.org.uk.
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2 Detailed sample service
specifications – pharmaceutical
services to drug users
• This sample service specification is evidence-based 
and reflects Models of care for treatment of adult drug
misusers update (NTA 2005) and the Drug Misuse and
Dependence: Guidelines for Clinical management
(Departments of Health 1999) as well as the legal and
ethical frameworks under which pharmacists are required
to practise
• This sample service specification is intended to provide
general guidance, and should not to be used as a fixed
and prescriptive template. The sample should be adapted
at local level, tailored to the particular type of providers
(pharmacists and pharmacies) and the interventions
purchased, and should not hamper the development of
innovative work
• It is good practice for commissioners to develop
specifications in partnership with service providers,
including prescribers, pharmacists, community
pharmacies and local pharmaceutical committees (LPCs),
in consultation with service users and carers
• This sample service specification should be read in
conjunction with section 3.1 of the NTA commissioning
drug treatment systems – resource pack for
commissioners (introduction, contracts, service
agreements and specifications)
• See also the NTA briefings Needle exchange and harm
reduction (NTA, 2003) and Community prescribing 
(NTA, 2003).
2.1  Definition of the services
The following service specifications are intended for the
purchase of pharmaceutical services for adult drug users
(those aged 18 years and over). These specifications form
the basis for providing pharmaceutical services to drug
users within the community in which they reside or work.
Models of care: Update 2005 (NTA 2005) places a greater
focus on the need to improve the effectiveness of drug
treatment systems by:
• improving interventions to reduce the risk of blood-borne
virus (BBV) infection and risk of overdose
• improving retention in drug treatment 
• improving drug treatment delivery, completion and
reintegration into communities.
Pharmaceutical services to drug users may involve both
community and hospital pharmacists,
In addition, PCT and PCO pharmacists will be involved in
their organisations’ commissioning of enhanced
pharmaceutical services, such as pharmacy needle
exchange and supervised consumption of prescribed oral
drugs. The development of enhanced services should be
informed or directed by the pharmaceutical needs
assessment (PNA) that PCTs and PCOs are advised to
undertake. PCTs, PCOs and DATs need to work together to
ensure pharmacy service provision matches local need for
drug and alcohol services.
All DATs, PCTs and PCOs are expected to ensure there is
widespread provision of:
• pharmacy needle exchange services 
• dispensing, supervised consumption and shared care
services for drug users involving pharmacists.
It is considered good practice that there is a named person
who is responsible for co-ordinating pharmacy needle
exchange schemes, supervised consumption and shared
care schemes (although it need not necessarily be the
same person). Co-ordinators can be employed by the
provider organisation, PCT, PCO, DAT, or another
organisation such as the hospital trust pharmacy
department.
In addition, there are a wide range of pharmaceutical
services which many pharmacists can and do provide.
Commissioners should work with pharmacists in the
community, hospitals, PCTs and PCOs to ensure that a
broad range of pharmaceutical services are available for
drug users. (See Section 3: Clarifying current and future
roles for pharmacists in the provision of services to
substance users.)
An individual pharmacy may be limited in the range of
services that it can provide. However, commissioners
should ensure that a full range of interventions can be
provided within local systems. The eventual aim should be
for the majority (over 75 per cent) of community pharmacies
to provide dispensing, supervised consumption and shared
care, so that individual patients have maximum choice on
where to have their prescription dispensed. In addition, the
aim should be that a significant proportion (over 25 per
cent) provide needle exchange, distributed appropriately
across the DAT, PCT and PCO localities.
Needle exchange and supervised consumption form part
of the enhanced services tier of the new community
pharmacy contract. Appendices 3 and 4 detail the
enhanced service specifications for pharmacy needle and
syringe exchange, and supervised consumption of
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prescribed oral medicines. These enhanced services are
locally commissioned by PCTs and PCOs. (See Appendix 2
for more information.)
In addition to services provided by community pharmacists,
pharmacists may be employed as part of specialist
community-based prescribing services that deal exclusively
with people with drug (and alcohol) misuse problems. 
Such services are usually staffed by a multidisciplinary team
of people with specialist knowledge in the field and led by
an addiction specialist. Pharmacists may be either directly
employed in such services to provide a wide range of
pharmaceutical services for drug (and alcohol) users, which
may include needle exchange and supervised consumption.
Alternatively, pharmaceutical advice and services may be
provided by the hospital pharmacy department of the
specialist service NHS trust.
Pharmacies where the pharmacist has undertaken specific
training and attained the required level of expertise and
competence may be able to offer additional services to
clients, which further support the NTA’s treatment
effectiveness strategy to promote progression through 
the treatment system for all individuals.
2.1.1  Pharmacy needle exchange – definition 
of service
Models of care: Update 2005 (NTA 2005) classifies
pharmacy needle exchange as a Tier 2 intervention.
Pharmacy-based needle exchanges are an important, 
easily accessible public health intervention. Pharmacy
needle exchange and harm reduction initiatives are
developed as part of the overall wider approach to prevent
the spread of blood-borne diseases (most particularly HIV
and hepatitis) and other drug-related harm, including 
drug-related death. They often have contact with drug 
users who are not in touch with other specialist treatment
services. They have a health remit as well as a social
welfare role within the wider community.
The local pharmacy needle exchange provision:
• must ensure the service is integrated and co-ordinated
with the overall local needle exchange and harm
reduction facilities
• should, as part of the overall needle exchange service,
meet the demands of the local population, for example, in
terms of geographical spread across the locality, opening
times and accessibility
• should include the distribution and collection of 
sterile injecting equipment and associated materials 
and their safe disposal. They should promote safe
injecting practices, to reduce transmission of infections
by drug users
• should provide the necessary level of privacy to clients,1
for example the availability of a private area or consulting
room.2 Particular consideration should be given to the
safety of pharmacy staff using completely closed
consultation rooms (advice on this is available from the
NHS Security Management Service)
• should ensure the ongoing provision of a range of other
harm reduction support and advice for the users of the
service, including referral to primary care and specialist
drug and alcohol services where appropriate
• must have agreement by providers and commissioners
on whether or not the provision of services to steroid
users is within the remit of the scheme.
DATs or commissioning partnerships should not depend
solely on community pharmacies for harm reduction and
needle exchange services, although these provide a
particularly important service. Pharmacy needle exchanges
should be seen as complementary to specialist services
rather than alternative settings. A range of models of
reaching and engaging with those at risk of drug-related
harm should be commissioned, including intensive harm
reduction work with those most at risk.
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2The new community pharmacy contract requires pharmacies that opt to provide the advanced tier of services to have private consultation facilities
in place. These consultation areas or rooms must allow the patient and pharmacist to sit down together and talk, without being overheard by other
people in the pharmacy. The area must be clearly designated as being for private consultations. As this national requirement will increasingly be
met by community pharmacies, commissioners may wish to set local criteria with these requirements in mind. 
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Commissioners and providers may agree to the separate
commissioning of the different elements which may
additionally be needed to complement the pharmaceutical
needle exchange service, for example:
• Co-ordination of the scheme including co-ordination 
with other harm minimisation services
• Supply of equipment (needles, syringes, sharps bins 
and associated paraphernalia) for the scheme
• Packing and delivery of equipment
• Collection of clinical waste, i.e. sharps bins 
and used equipment
• Sourcing and distribution of leaflets, information, 
printing and stationery
• Training of pharmacy staff
• Payment systems (see Appendix 1, section 5.4)
• Support for pharmacists and staff 
• Hepatitis B vaccination for staff and clients.
Commissioners should investigate the potential for 
co-funding with other organisations and funding streams –
for example DAT and pooled treatment budgets, social
services, drug intervention programmes (DIPs), probation,
local authorities and HIV funds.
2.1.2  Dispensing, supervised consumption and shared
care – definition of service
Models of care: Update 2005 (NTA, 2005) recognises that
community-based drug treatment can provide a range of
interventions spanning across both Tier 2 and Tier 3.
However, it also acknowledges that all substitute
prescribing interventions should be redefined as Tier 3. 
This is because they require comprehensive assessment,
should be care planned and carry a high duty of care
for the clinician prescribing (and the pharmacist dispensing)
controlled drugs.
Shared care is defined as: “the joint participation of
specialists and GPs (and other agencies as appropriate) 
in the planned delivery of care for patients with a drug
misuse problem, informed by an enhanced information
exchange and beyond routine discharge and referral letters.
It may involve the day-to-day management by the GP 
of the patient’s medical needs in relation to their drug
misuse. Such arrangements should make explicit which
clinician is responsible for different aspects of the patient’s
treatment and care. These may include prescribing
substitute drugs in appropriate circumstances (Drug misuse
and dependence: Guidelines on clinical management,
Departments of Health, 1999).” Pharmacists providing
shared care will share relevant information with other
healthcare professionals and agencies, in line with locally
determined confidentiality arrangements. 
Pharmacy dispensing, supervised consumption and shared
care services for drug (and alcohol) dependent adults are
therefore Tier 3 and include those patients3 prescribed:
• for opioid dependence (titration, detoxification and
reduction) and maintenance regimens (such as
methadone or buprenorphine4)
• for withdrawal from opioids with non-opioid medications
(e.g. lofexidine)
• for stabilisation and withdrawal from sedatives, where
appropriate (such as benzodiazepines and alcohol)
• for relapse prevention where appropriate 
(e.g. naltrexone, disulfiram) 
• for dependent stimulant use, including symptomatic
treatment medications (although some substitute
prescribing for amphetamines does occur there is still 
no national consensus on its appropriateness and the
evidence base remains limited).
Pharmacists will continue to provide shared care for
patients whether or not doses are prescribed to be
administered under the supervision of the pharmacist.
Pharmaceutical services to drug users must:
• be integrated and co-ordinated with the local 
prescribing services and treatment systems
• meet the demand of the local population and 
prescribing services 
• provide the necessary level of privacy to clients, for
example the availability of a private area or consulting
room.2 Particular consideration should be given to 
the safety of pharmacy staff using completely closed
consultation rooms (advice on this is available from 
the NHS Security Management Service).
12
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In addition:
• Arrangements must be in place to cover situations where
patients choose to use a pharmacy outside the DAT, PCT
or PCO area. (See Appendix 1: section 4.6 for further
guidance. In general, pharmacies will be paid for
contracted services by their PCTS and PCOS,
irrespective of where the prescription originates, but
some commissioners will restrict the provision of services
to people resident in their area.) 
• The provision of this service includes ensuring 
patients have:
– access to a daily dispensing service (excluding
Sundays and bank holidays)
– access to a daily supervised consumption service 
for prescribed oral medicines (excluding Sundays 
and bank holidays), which ensures the prescribed
dose has been administered to the patient.
And that:
– Relevant information can be shared between the
healthcare professionals about the drug user without
compromising the individual’s rights (for all patients
prescribed for according to the specification) 
– the ongoing provision of a range of other harm
reduction support and advice for the users of the
service, including referral to primary care and specialist
drug and alcohol services, is available where
appropriate.
Commissioners may commission the different elements
which may additionally be needed to complement the
pharmacy dispensing, supervised consumption and shared
care services, for example:
• leaflets, information, printing and stationery
• training of pharmacy staff
• co-ordination of the scheme including with various
prescribing services, e.g. secondary care, primary care
and the Drugs Intervention Programme (DIP)
• support for pharmacists and staff
• hepatitis B vaccination for staff and patients.
2.2  Aims and objectives of the services
The overall aims of pharmacy services to drug users are:
• to offer user-friendly, non-judgmental, confidential and
user-centred services
• to liaise with healthcare professionals and others involved
in the care of the patient having due regard for the
patient’s confidentiality
• to help the service user to remain healthy and reduce
drug related harm
• to reduce health problems related to drug misuse
• to reduce the dangers associated with drug misuse,
including the risks of HIV, hepatitis B and C, other blood-
borne infections and the risks of drug-related death
• to provide and reinforce focused harm reduction advice
and initiatives, including advice on overdose
• to facilitate access to primary care where relevant 
• to provide service users with regular contact with a
healthcare professional and to help them access further
advice or assistance. The service user will be referred to
specialist treatment centres or other health and social
professionals where appropriate.
2.2.1  Pharmacy needle exchange – aims and objectives
• To reduce the rate of sharing and other high-risk injecting
behaviours by providing sterile injecting equipment and
other support
• To promote safer injecting practices, to reduce the risk of
blood borne virus (BBV) infection and risk of overdose
• To help service users access other health and social care
and to act as a gateway to other services (e.g. key
working, prescribing, hepatitis B immunisation, hepatitis
and HIV screening, primary care services etc)
• To ensure the safe disposal of used injecting equipment
• To maximise the access and retention of all injectors,
especially the highly socially excluded, through the low-
threshold nature of service delivery and interventions
provided
• To prevent initiation into injecting and to encourage
alternatives to injecting.
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2.2.2  Dispensing, supervised consumption and shared
care – aims and objectives
• To ensure compliance with the agreed treatment plan by:
– dispensing prescribed medication in specified
instalments
– ensuring each supervised dose is correctly
administered to the patient for whom it was intended
(doses may be dispensed for the patient to take away
to cover days when the pharmacy is closed)
– liaising with the prescriber, named keyworker and
others directly involved in the care of the patient
(where the patient has given their written permission)
– monitoring the patient’s response to prescribed
treatment; for example, if there are signs of overdose,
especially at times when doses are changed, during
titration of doses, if the patient appear intoxicated or
when the patient has missed doses, and, if necessary,
withholding treatment if this is in the interest of patient
safety, liaising with the prescriber or named keyworker
as appropriate
– improving retention in drug treatment 
– improving drug treatment delivery and completion.
• To reduce the risk to local communities of:
– overuse or underuse of medicines
– diversion of prescribed medicines onto the illicit 
drugs market 
– accidental exposure to the dispensed medicines.
2.3  Service user group served
2.3.1  Pharmacy needle exchange – client group served
Pharmacy needle exchange facilities are available to all
adult injectors who are using drugs illicitly, but special
attention should be given to clients who are not in touch
with drug and alcohol misuse treatment services.
Where possible, needle exchange and harm reduction
facilities should also provide interventions relevant to 
non-injectors. These include, but are not limited to:
• interventions to prevent transition into injecting
• interventions aimed at reducing the harm of smoking
crack cocaine (see NTA’s service specifications and
guidance on working with crack users) 
• interventions aimed at reducing harm of other drugs 
(e.g. cannabis and ecstasy).
These interventions should be adequately resourced.
2.3.2  Dispensing, supervised consumption and shared
care – patient group served
The target group for community-based dispensing and
shared care is individuals, in receipt of an NHS
prescription, who have drug-related problems, including
dependent opioid users as well as those who present with
additional polydrug use or concurrent use of
benzodiazepines, psychostimulants and alcohol.
Pharmacists are required to dispense NHS prescriptions
with reasonable promptness and provide, when requested
(for example by the prescriber), supervised consumption of
certain specified medicines (most commonly methadone
oral mixture 1mg in 1ml and sublingual buprenorphine
tablets).
Supervised consumption is not part of the dispensing
process and will not be provided by the pharmacist, except
as part of an agreed scheme.
2.4  Contraindications and exclusions
Models of care: Update 2005 (NTA 2005) focuses on 
the commissioning of services for adults (those aged 
18 years or over).
A person aged 17 years or under who requires 
treatment will normally access a young person’s service.
Commissioners of both adult and children’s services 
need to have plans in place to ensure a smooth referral 
and transition between their services. It is possible 
that the young person will remain with the same pharmacy
after transferring to the adult service.Service users should
only be excluded for behaviour that has breached
accepted rules and standards at the discretion of the
pharmacist but within a structure of users’ rights and
responsibilities. Service users may be excluded as a result
of a professional risk assessment and if they pose a
serious risk to staff, other service users and members of
the public. Where appropriate, work is carried out to re-
engage drug users in this or other more appropriate
services and referral to more appropriate services is made
where possible.
2.4.1  Pharmacy needle exchange – contraindications
and exclusions
For guidance on work with young people refer to Making
harm reduction work. Needle exchange for young people
under 18 years old (Drugscope and Department of Health,
2001). Commissioners and providers must agree
arrangements for young people who request needle
exchange from a participating pharmacy.
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2.4.2  Dispensing, supervised consumption and 
shared care of substitute medication – contraindications
and exclusions
For guidance on dispensing, supervised consumption 
and shared care refer to Drug misuse and dependence –
guidelines on clinical management (Departments of 
Health, 1999).
2.4.2.1  Dispensing
The pharmacist cannot dispense the prescription if it does
not fully comply with legal requirements.
Dispensing and supply can be refused in certain
circumstances, as defined by the new pharmacy contract:
• If the pharmacist believes the prescription is not genuine
or for the person named on the prescription form
• If the pharmacist believes the prescriber has made 
a clinical error or that the prescription is clinically
inappropriate
• If the patient or anyone with them behaves or threatens
to behave violently, or commits or threatens to commit
any criminal offence (in the pharmacy).
Patients may be excluded as a result of a professional risk
assessment – this can include patients who have, for example:
• missed collecting their prescribed medicine for a
specified number of instalments and their tolerance to 
the drug may have reduced 
• those who appear intoxicated. Patients must be informed
prior to initiation of treatment what types of behaviour
may result in exclusion.
2.4.2.2  Supervised consumption of substitute
medication (including shared care)
Commissioners must clearly identify and agree with
providers which patients are included or excluded – 
in particular, whether shared care will be expected 
to continue whether the patient is supervised or not. 
This will depend upon what service is required from 
the community pharmacies and, where appropriate, 
specialist team pharmacists, for example, does the 
service commissioned include or exclude:
• patients prescribed using FP10MDA (or the equivalents
from Wales, Scotland and Northern Ireland), i.e.
instalment prescriptions?
• patients prescribed methadone mixture 1mg in 1ml or
buprenorphine sub-lingual tablets?
• patients prescribed injectable opioid substitute treatment
(diamorphine, methadone)?
• patients prescribed within the local ‘shared care model’?
• patients in ’shared care’ but no longer required to be
supervised?
• patients who have been started in shared care but are
now on a maintenance prescription from a GP and are no
longer considered necessary to be part of the local
shared care model?
• patients prescribed for by the local specialist substance
misuse services?
• patients prescribed for by named GPs?
• patients prescribed for by any GPs in the local DATs,
PCTs and PCOs?
• patients prescribed for by a supplementary prescriber?
• patients prescribed for by GPs and specialist services
outside the DAT or commissioned area?
• patients prescribed for by UK prescribers outside
England?
• patients whose treatment has been initiated by the
specialist services?
• patients prescribed other drugs, for example,
benzodiazepines, naltrexone, or disulfiram?
• patients prescribed for by the Drugs Intervention
Programme (DIP)?
• patients released from prison? 
• patients prescribed for by another treatment service not
commissioned by this DAT or PCT?
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2.5  Referral pathways
2.5.1  Access and referral
Provider opening times should be clearly displayed and
service users must be given clear information when there 
is any variation, if the service is not available during these
times. Providers and commissioners should ensure that
service users have access to services at as wide a range 
of times as possible. Commissioners should work with
providers to ensure a service is available over as many 
days and for as many hours a day as possible.
Providers must ensure service user confidentiality is
maintained to avoid service users being prevented from
accessing services, as a result of concerns that they will 
be recognised or identified as a drug user.
Whenever possible and where appropriate, pharmacy
service providers should facilitate onward referral to
specialist drug treatment services, GPs, other healthcare
professionals in primary care, accident and emergency
departments or minor injuries units.
2.5.1.1  Pharmacy needle exchange
Access to pharmacy needle exchange facilities and harm
reduction initiatives is voluntary and open. Referrals are
accepted from a wide variety of sources, with self-referral
being the most usual route of access, and do not require
contact with other drug misuse treatment and care agencies.
Patients who are receiving prescribed medication (for
example opioid substitution treatment) will not be refused
access to clean injecting equipment and needle exchange,
and this service will be provided confidentially by the
pharmacist. In such circumstances, the pharmacist will
generally, where appropriate, encourage the client to
discuss this with their doctor or keyworker.
Whenever possible and where appropriate, pharmacy
service providers should facilitate onward referral to
specialist drug treatment services, GPs, other healthcare
professionals in primary care, accident and emergency
departments or minor injuries units.
Pharmacy service providers will encourage clients to
register with a GP.
2.5.1.2  Dispensing, supervised consumption and 
shared care – access and referral
Access to treatment in a pharmacy is voluntary. Patients
have the right to choose which pharmacy they have their
prescription dispensed at. It is inappropriate for prescribers
to direct patients to individual, named pharmacies.
Commissioners and providers must work together to ensure
the overall capacity of the local dispensing system is sufficient
to meet the combined demand from all the various prescribing
services. It is good practice for prescribers to contact the
patient’s chosen pharmacy prior to initiating prescribing, as
some pharmacies may not have the capacity to take on new
patients. Capacity may be increased, for example, by:
• improving consultation areas
• providing larger controlled drugs cabinets
• improving security 
• reducing dispensing time by the use of automatic 
“bottle-top” dispensers and the use of electronic systems
for controlled drug record keeping.
Providers must work with prescribers to find ways of
minimising delays for patients accessing pharmaceutical
services, for example by:
• improving systems to verify that the prescriber and the
patient are genuine, before dispensing a prescription
• ensuring prescriptions comply with all current legislation
prior to dispensing
• arranging for prescriptions to be sent direct to the
pharmacy in advance of the patient, where appropriate 
• facilitating pharmacies dispensing the prescribed
medicine for the first time (i.e. where the pharmacy may
not have the item in stock).
Access to a supervised consumption service will only be
provided where there is an agreed funded service.
2.5.2  Basic assessment and ongoing harm reduction
advice and support
Pharmacists or other appropriately trained pharmacy staff
should provide direct input wherever possible to promote
harm reduction including:
• recognising people with physical health problems or
severe mental health problems and referring them to
appropriate services
• carrying out risk assessments and identification of
immediate risks (e.g. injection site injuries, harm to 
others, and physical and mental health emergencies) and
providing advice, treatment and referral as appropriate
• actively encouraging service users to access hepatitis B
immunisation and to complete the course
• emphasising the risks of overdose, strategies to reduce
those risks and to respond to overdose (including
polydrug use and alcohol misuse) 
• advising on safer sex, sexual health, HBV immunisation
and HBV, HCV and HIV testing.
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Harm reduction work should be provided in a form that is
appropriate to the needs and desires of the service user.
Interventions should include a clear health promotion element.
2.5.2.1  Pharmacy needle exchange – ongoing support
and advice
A comprehensive assessment of needle exchange 
clients is not required, especially if it constitutes a barrier 
to service utilisation.
Commissioners and providers should agree the level 
of harm reduction advice and support to be provided.
Messages have to be periodically reinforced.
• As a minimum, all clients must be:
– informed of drug (and alcohol) treatment services in
their locality, with clear information on referral and
eligibility criteria
– encouraged to register with a GP
– provided with details of other pharmacy and non-
pharmacy needle exchange services in the locality
– provided with information about harm reduction and
harm reduction services (e.g. advice, information and
details of support agencies)
– provided with information on overdose risks
– informed about the reasons for providing injecting
equipment and the risks of sharing injecting
equipment, unsafe injecting and sexual practices
– informed about the risks of unsafe disposal of 
injecting equipment
– informed of alternatives sites for safe disposal of used
injecting equipment 
– the importance of always returning used equipment 
for safe disposal.
• Additional services, offered by some pharmacy needle
exchange providers to ensure that harm reduction is
ongoing, include but are not limited to:
– risks of unsafe injecting practices (local and systemic
infections, including HIV, HBV and HCV, venous and
arterial thrombosis, avoiding site infections, abscesses,
damaged blood vessels, TB and endocarditis)
– safer injecting practices, including hygiene advice, 
vein care and information on related equipment 
and paraphernalia
– alternatives to injecting
– information about the range of services provided by
needle exchange schemes, other drug treatment
services and other health and social care services 
– harm reduction information specific to the drug
injected (e.g. information is given to amphetamine and
other stimulant users about the increased levels of
paranoia, hallucinations and violent behaviour resulting
from injecting).
– Access to on-site services such as blood-borne 
virus (BBV) testing, hepatitis immunisation, tetanus
booster vaccination, checking of injection sites,
wound care, health checks and diagnostic checks
(which could be provided by the pharmacist or
provided by a nurse on site).
2.6  Care planning
2.6.1  Pharmacy needle exchange
A care plan for clients of pharmacy needle exchange
facilities is not required. It is good practice for needle
exchanges to work to engage clients in the development 
of a brief and basic plan that identifies goals and milestones
for changes in risk behaviours and harm reduction.
However, this should not be a prerequisite for accessing
clean injecting equipment. It should not constitute a barrier
to service utilisation, in particular when the client first
accesses the pharmacy.
Pharmacy staff should reinforce the harm minimisation
message and encourage hepatitis B immunisation and
course completion.
Reviews of the needs of clients should be possible.
2.6.2  Dispensing, supervised consumption and shared
care – care plans
All patients should have a written and structured care plan
resulting from assessment, prior to prescribing. Care plans
are developed with the active participation of patients and
take into account their wishes and needs. Care plans are
tailored to patients’ needs and circumstances and respond
flexibly to the patients’ problems.
Providers should work with prescribers, keyworkers and
care co-ordinators to ensure the name of the patient’s
chosen pharmacy is included in the prescriber’s care plan.
The Departments of Health’s Drug misuse and dependence
– guidelines on clinical management recommends the
inclusion of the pharmacist in shared care as a model of
good practice and the pharmacist should liaise with the
multidisciplinary team on a regular basis.
• A care plan review does not necessarily require a case
conference of all providers involved in the care of
individuals. For example, prescribers (e.g. GPs or
specialists) can undertake the review during an ordinary
appointment and decisions are discussed with other
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professionals and fed into the joint care planning process.
Pharmacists will be expected to contribute to this 
process, for example, by providing regular verbal and
written reports on issues that may be of concern, or may
help demonstrate the improvement in the patient’s health.
However, commissioners need to recognise that where
pharmacists are required to attend team meetings, they will
require payment of locum and possibly other expenses.
Pharmacists will be able:
• to work with the different prescribing services as 
patients move through treatment. Patients will be
encouraged to remain with the same pharmacy, 
providing a valuable, constant, and regular link with 
the same healthcare professional
• to refer patients experiencing difficulties back to the
prescriber or keyworker for reassessment 
• to withhold treatment if this is in the interest of patient
safety; for example, during titration of doses, if the patient
has missed doses or is intoxicated and to liaise and
agree with the prescriber or keyworker the appropriate
ongoing treatment with future doses
• to provide a routine assessment of stabilised patients, for
example for side effects, concordance issues, symptoms
of withdrawal, intoxication, and childcare issues.
Commissioners should ensure shared care arrangements
continue to include the pharmacist as the patient moves
between different prescribing services.
2.7  Co-ordination of care
2.7.1  Dispensing, supervised consumption 
and shared care
Pharmacists will support the keyworker responsible for 
co-ordinating the patient’s care by monitoring continuity 
of care and contributing to the aim of maximising retention
of patients in the treatment system:
• by reporting when patients drop out of treatment (e.g.
when doses are not collected)
• by reporting any relevant concerns about the patient
• by providing relevant information when requested by care
co-ordinators and keyworkers.
Pharmacists will share relevant information with other health
professionals (including keyworkers) and agencies, in line
with locally determined confidentiality arrangements.
2.8  Description of services, 
care and interventions provided
The following section describes the services, care and
interventions that most participating pharmacists and
pharmacies are expected to provide when offering needle
exchange and dispensing, supervised consumption and
shared care services.
However, commissioners, DATs, PCTs and PCOs should
take advantage of the opportunities to engage pharmacists
more fully in the planning, provision, delivery and extension
of services for substance users. Pharmacists and their staff
make a considerable contribution to the prevention of
substance misuse and the care and treatment of drug and
alcohol users, but there are significant opportunities to
improve and develop these services. In some cases, this
can be managed as part of the essential and enhanced
services of the pharmacy contract. (See Appendix 2).
Pharmacists can be involved in strategic and operational
planning, with implementation supported by pharmacists
with specialist knowledge of substance misuse and its
treatment. This can be achieved through the inclusion of
specialist pharmacy representation on:
• drug (and alcohol) action teams 
• share care monitoring groups
• multidisciplinary teams.
This will ensure access to specialist pharmacist advice on
all areas of substance misuse.
• Pharmacy service providers enhance engagement in
treatment and motivation for change by paying special
attention to (in respect of substance misusers):
– Good pharmacist and staff interpersonal skills
– Good pharmacist and staff-service user relations
(including feeling that they are listened to, concerns
are understood, helpful responses are provided,
pharmacist-staff empathy is shown and there is a
good rapport with drug users)
– Working to enhance patients’ perceptions of the
helpfulness of a service
– Working to improve patients’ confidence in
pharmaceutical care.
Pharmacists will liaise, within the bounds of their
professional code of ethics and the RPSGB Medicines,
Ethics and Practice confidentiality guidelines, with:
• the local scheme co-ordinator
• the local commissioning authority
• drug addiction clinics and drug teams 
• the police, to collaborate on general issues.
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Pharmacists will ensure there is appropriate professional
indemnity and insurance for staff and premises providing
commissioned services.
Scheme co-ordinators will ensure they are in regular 
contact with participating pharmacies. They will ensure
pharmacists and staff are supported in their role and will
further encourage new pharmacies to join schemes.
Tasks of the role of co-ordinator include but are not limited to:
• Liaison between primary care and specialist drug and
needle exchange services
• Ensuring lines of communication are open and effective
• Provision of clear protocols
• Delineating clear roles and responsibilities of all parties
involved in needle exchange and shared care to ensure
services are harmonised
• Ensuring robust clinical governance pathways
• Ensuring an appropriate audit of clinical activity and
performance management.
2.8.1  Pharmacy needle exchange – description
Providers and commissioners should agree funding. 
The services, care and interventions offered by a pharmacy
needle exchange will depend on the level of competence
and training achieved by the individual pharmacists and
staff at each pharmacy.
Services, care and interventions offered can include, 
but are not limited to:
• Screening, risk assessment and referral:
– referral to appropriate services to access psychosocial
interventions or advice on health, social and legal
problems
– referral to other treatment services and assessment
where appropriate
– basic health examinations, including checks on
injection sites, first aid, dealing with minor infections
(including, where possible, using patient group
directions to supply prescription-only medicines and
dressings), provision of medicines through a local
minor ailment scheme, health checks and diagnostic
tests, or referral to appropriate services
– referral to immunisation services and, where possible,
on-site immunisation (e.g. pharmacy needle
exchanges where pharmacist, using a patient group
direction, has received training and has necessary
level of private area on site) 
– brief interventions for alcohol misuse.
• Advice – including handing out written information and
verbal information:
– pharmacy needle exchange providers should
encourage and support motivation for change and
treatment readiness where relevant
– provide advice on safer injecting practices (risks of
sharing, lending and borrowing injecting equipment,
filters, spoons and water), including avoiding injection
site infections
– risk reduction advice and health promotion. This
includes advice on a range of issues including the
prevention of drug related death, preventing blood-
borne infections, contraception and safer sex, alcohol
misuse, nutrition, dental health, care of minor infections
– advice on legally available paraphernalia including
whether and where this can be accessed by clients if not
available via the pharmacy needle exchange scheme
– periodic development of a range of harm reduction
and health promotion campaigns
– advice on prevention of HIV, hepatitis and other drug-
related problems
– advice and information on HIV and hepatitis B 
and C testing, or referral to testing
– encouragement to complete vaccination courses
– overdose prevention and response advice and
information
– advice specific to the drug injected (including
stimulants and steroids)
– advice on the safe storage and handling of 
injecting equipment
– advice on safer sex and sexual health
– advice and interventions that prevent or curtail
transition into injecting. These interventions should 
be targeted at current injectors and smokers of
substances that can be injected 
– advice and interventions on drug-related harm that
does not involve injecting (e.g. harm related to
smoking crack).
• Handing out equipment:
– distribution of a range of free sterile needles and
syringes5
– safe disposal of injecting equipment, including supply
of personal sharps bins
– distribution of other appropriate harm minimisation
injecting paraphernalia. Changes in Section 9A of the
1971 Misuse of Drugs Act now allow the lawful supply
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of certain articles of drug paraphernalia to drug users
for harm minimisation purposes, specifically swabs,
spoons, bowls, filters, citric acid, ascorbic acid and
water for injections (containing not more than 2ml of
sterile water)
– consistent effort to maximise return of used injecting
equipment. A failure to return used equipment should
not automatically result in a denial of further supply.
2.8.2  Dispensing, supervised consumption and shared
care – description
Providers and commissioners should agree funding. 
The services, care and interventions offered will depend 
on the level of competence and training achieved by the
individual pharmacists and staff at each pharmacy.
Services, care and interventions offered can include, 
but are not limited to:
• Dispensing
– For titration of treatment
– For reduction and detoxification regimens
– For long-term dispensing for harm minimisation (e.g.
methadone or buprenorphine maintenance treatment).
• Supervised consumption
– Which ensures the dose of a drug prescribed has been
administered to the patient at the point of dispensing.
– In the case of methadone, this will include specific
measures to ensure the dose has been swallowed; 
for example, the patient should be offered a drink of
water and asked to speak after consuming the dose,
to demonstrate the dose has been swallowed.
– In the case of buprenorphine, providers and
commissioners will need to agree what is the
maximum amount of time that the pharmacist should
spend in supervising consumption of each dose, as
dissolution of the sublingual tablets may take several
minutes. If a local decision is made for tablets to be
crushed prior to supervising consumption, then this
must be supported by the shared care monitoring
group and the chief pharmacist of the PCT, PCO or
local NHS trust, to ensure strict clinical governance
processes are in place as this is an unlicensed use of
the medicine. Pharmacists should ensure that their
indemnity insurance covers such activity. Pharmacists
should not crush buprenorphine tablets prior to
administration, without the permission of the prescriber
and the patient (Society guidance for buprenorphine
tablets, RPSGB, March 2005).
• Shared care
– Such that there is sharing of relevant information with
other healthcare professionals and agencies, in line
with locally determined confidentiality agreements
– Continued dispensing, (and supervised consumption 
if requested) and shared care arrangements, for
patients who move from one prescriber to another, 
as patients often remain with the same pharmacy.
Pharmacists will provide a valuable link between
different prescribing agencies.
• Screening, risk assessment and referral
– Pharmacists feed back appropriate information to
keyworkers and prescribers with the agreement of the
patient, in accordance with their professional code of
practice and the local shared care arrangements
– Pharmacy service providers make a clinical judgement
as to when it may be appropriate to withhold a dose,
e.g. during dose titration, if the patient is intoxicated
with drugs or alcohol, if there are signs of overdose, 
if the patient has missed three days’ prescribed
treatment (or the assigned number of days as defined
in any local agreement), or if the pharmacist has cause
for concern about the patient’s safety
– Referral to appropriate HIV and hepatitis testing services
and encouragement to complete vaccination courses
– Advice or referral to appropriate services on relapse
prevention as a component of the treatment programme
– Referral for assessment for access to appropriate
treatment services (e.g. the local community drug service)
– Referral to practical social support (e.g. housing,
welfare benefits and legal advice)
– Referral to appropriate counselling services.
• Advice, including handing out written information and
verbal information
– Patients are prepared for the provision of substitute
medications from a pharmacy. This includes advice
and written information about methadone,
buprenorphine or other pharmacotherapy, alcohol use,
risks of overdose, loss of tolerance following missed or
uncollected doses, drug interactions, an explanation of
supervised consumption and where and how this will
occur, and opening and closing times.
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– Advice on a range of issues including the prevention of
drug-related death, overdose prevention, blood-borne
infections, oral health, sexual health, contraception and
safer sex, nutrition, minor infections, wound dressings,
dental health and nicotine replacement therapy.
• Legal and professional responsibilities
– Ensuring the legality of the prescription and
correctness of detail
– Registering the patient onto the Patient 
Medication Record
– Dispensing the medicine in accordance with 
the prescription system
– Explaining that missed doses cannot be 
collected the next day
– Following local agreed arrangements (via the shared
care monitoring group) allowing the dispensing and
supervised consumption of doses not collected on
specified days – in accordance with Home Office
guidance on instalment prescribing (Reference
Pharmaceutical Journal Volume 274, number 7347,
30th April 2005 page 531)
– Pharmacy service providers co-operate with the
chemist inspecting officer and the RPSGB inspector,
as required by the professional code of practice 
(and future inspection bodies introduced following 
the Shipman Inquiry)
– Compliance with current legislation, including the
Medicines Act 1968, Misuse of Drugs Act 1971,
Misuse of Drugs Regulations 2001 as amended,
Misuse of Drugs (Safe Custody) Regulations 1973,
National Health Services (Pharmaceutical Services)
Regulations 2005.
2.9  Competencies and training
All pharmacists must have an appropriate level of
competency to undertake these services – this will be
determined by the requirements of the enhanced services
within the new pharmacy contract and local agreements
prior to commissioning of the service.
The training of pharmacists and their staff should be
determined by competency analysis based on the Drug and
Alcohol National Occupational Standards (DANOS). The
RPSGB has a range of policies covering minimum training
and competence requirements for pharmacy support staff,
including pharmacy technicians, medicines counter
assistants, and dispensing and pharmacy assistants.
Providers must ensure staff are trained to provide the
appropriate level of service. Pharmacists and their staff will
adhere to the standards and practice guidance set by the
RPSGB for the provision of services to drug misusers and
needle exchange services in community pharmacies. These
standards are detailed in Medicines, ethics and practice: a
guide for pharmacists (RPSGB, latest edition).
Health and safety training is provided to staff, including
training on the handling of injecting equipment.
Pharmacists are encouraged to complete the two open
learning modules, Substance misuse and opiate treatment:
Supporting pharmacists for improved patient care, provided
by the Centre for Pharmacy Postgraduate Education (CPPE)
in England, or the equivalent distance learning packs
available from the Scotland, Wales and Northern Ireland
Centres for Pharmacy Postgraduate Education. An open
learning module on substance misuse should be available
from CPPE for pharmacy technicians in summer 2006.
In addition, the National Pharmacy Association (NPA)
provides its members with a resource manual on operating
a pharmacy needle exchange, as do some multiple
pharmacy chains.
Training must be updated regularly in response to changes
in drug use, risk behaviours, BBVs, harm minimisation, 
local and national policies and legislation. This may be
through formal training events, newsletters, information
packs, telephone support and regular visits by the co-
ordinator. Pharmacy service providers are encouraged to
regularly refer to the substance misuse management in
general practice website (www.smmgp.org.uk) and join the
UK psychiatric pharmacists substance misuse e-mail 
group (www.ukppg.org.uk).
Pharmacists who have completed the CPPE open learning
module Substance misuse and intend to provide additional
or enhanced services to drug users may wish to complete
Part 2 of the Royal College of General Practitioners
Certificate in the Management of Drug Misuse in Primary
Care. Such pharmacists may then also provide support and
advice to other pharmacists. Pharmacists who have
completed and passed the Part 2 RCGP certificate may, 
in future, become pharmacists with a special interest
(PhwSI) in drug misuse. (The PhwSI framework is being
developed alongside the implementation of the new
community pharmacy contract.)
DATs, PCTs and PCOs should ensure commissioning of
services with both levels of competencies to ensure there is
a professional support structure for pharmacists providing
services to drug users to avoid the risk of community
pharmacists becoming isolated. Individual pharmacies and
pharmacists should be supported to ensure that they are
able to provide a service that conforms to the service
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specification. Involving all pharmacy staff as well as 
service users (or ex-service users) in pharmacy training
should be considered.
Barriers to recruitment of pharmacists and staff who provide
services for drug users can include pharmacist perception
of the client group, for example, the stigma attached to the
clientele, or the pharmacist does not want to appear to be
condoning illegal drug use. In addition, pharmacists may
stop providing services as a result of adverse incidents, 
for example, clients shoplifting, increased crime rates and
aggressive client behaviour. Commissioners and providers
should work together to ensure training and support
mechanisms cover effective ways to reduce and manage
such incidents.
Funding should be available for identified training needs.
2.10  Service principles
2.10.1  Pharmacy needle exchange
• Pharmacy needle exchange facilities and harm reduction
initiatives provide an easy, low-threshold, open access
and user-friendly service
• Pharmacists and their staff operating needle exchange
have standard operating procedures in place for their
individual premises
• Staff operating pharmacy needle exchanges should be
competent to provide information on the range of drugs
injected, including heroin, cocaine, crack cocaine,
amphetamines and steroids
• Advice and information is provided which is appropriate
and relevant to the needs of diverse populations and
literacy levels – available in a number of languages 
and suitable for the visually impaired, where relevant
• Pharmacy needle exchange and harm reduction
interventions should work with the full range of tiers, 
to integrate harm reduction initiatives into practice
• Pharmacy needle exchanges actively encourage returns
of used injecting equipment, but this should not be 
a condition for accessing sterile injecting equipment
• Injecting equipment and safe disposal of equipment 
must meet UK standards
• Pharmacists and pharmacies participating in a needle
exchange scheme must comply with the guidelines laid
down by the RPSGB, e.g. participating pharmacists and
their staff should be offered hepatitis B immunisation
• Pharmacists are provided with support (such as from 
a dedicated scheme co-ordinator) to operate the needle
exchange scheme
• Scheme co-ordinators ensure quality through appropriate
clinical governance arrangements
• Local communities are proactively consulted on
discarded used injecting equipment
• Pharmacies receive prompt payment for services provided
• Pharmacies are provided with regular supplies of required
equipment at levels required to meet clients’ needs
• The pharmacy needle exchange service is integrated 
and co-ordinated with other needle exchange and harm
minimisation provision in the locality.
2.10.2  Dispensing, supervised consumption and 
shared care – service principles
• There is a multidisciplinary approach to prescribing
(including GP prescribing) which is carried out in line with
the recommendations of Drug misuse and dependence –
guidelines on clinical management (DH,1999) and other
central guidance, and includes the patient’s pharmacist
• Pharmacists providing shared care, dispensing 
and supervised consumption services provide a user-
friendly service
• Pharmacists and their staff providing dispensing,
supervised consumption and shared care for drug users
have standard operating procedures in place for their
individual premises
• Pharmacists provide the service user with information
about their medicines
• Shared care, dispensing and supervised consumption
services are based on clearly defined protocols providing
both detoxification (reduction) and maintenance regimens
• The pharmacist ensures that supervised consumption
takes place in a private or quiet area of the pharmacy
• The pharmacist, as part of the multidisciplinary team, 
has measures in place to limit the leakage of prescribed
drugs to illicit markets (e.g. supervised consumption) 
and to prevent drug-related deaths. Pharmacists are
aware of exceptions when supervised consumption 
is not considered necessary or appropriate
• Pharmacists (or suitably trained, qualified or competent
members of staff) are required to supervise (when
prescribed or required) the consumption of the prescribed
oral medicine (e.g. methadone, buprenorphine) at the
point of dispensing, ensuring that the dose has been
administered to the patient. In certain circumstances,
pharmacists may initiate supervised consumption 
(e.g. where the prescriber has omitted to include the
direction to supervise on the prescription or where the
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patient requests supervised consumption), but this
should be with the agreement of other members of the
shared care team
• Patients are provided with support and advice, 
including referral to primary care or specialist centres
where appropriate
• Pharmacies participating in shared care, dispensing 
and supervised consumption services comply with the
guidelines laid out by the RPSGB
• Pharmacists will only dispense prescriptions which
comply with current legislation (e.g. Misuse of Drugs Act
1971, Misuse of Drugs Regulations 2001)
• Participating pharmacists have effective links with
prescribing services (including GPs) and provide advice
and shared care where required. Pharmacists liaise with
services (including GPs) about specific patients and
prescribing regimens. The pharmacist shares relevant
information with all professionals involved in the
treatment, within the bounds of pharmacists’ professional
confidentiality guidelines
• Pharmacists abide by local arrangements for clinical
governance (e.g. PCT, PCO or provider trust arrangements).
• Pharmacists are provided with support (for example, from
a dedicated scheme co-ordinator) to operate shared care
and supervised consumption schemes
• Pharmacies receive prompt payment for services
provided
• There is pharmaceutical representation on the local
shared care monitoring group. Decisions are to be agreed
at local levels, but should comply with central guidance.
2.11  Policies, protocols and written strategies
Pharmacy services commissioned should have all the
written polices and protocols identified in this briefing and 
in briefing 3.1 of the NTA commissioning drug treatment
systems – resource pack for commissioners (introduction,
contracts, service agreements and specifications).
All policies should have a named person (e.g. the scheme
co-ordinator) with responsibility for implementation and
monitoring and dates for review.
Commissioners should work with service providers 
to identify:
• gaps and priorities in service provision
• clear objectives and measurable targets
• timescales
• funding and other resources available
• monitoring requirements 
• agreed channels of communication with local
pharmaceutical committees (LPCs), PCTs, PCOs 
and trusts.
Pharmacy service providers will adopt the DAT, PCT 
or PCO strategy on:
• the reduction of drug-related deaths (blood-borne
infections and overdose prevention)
• hepatitis B immunisation, which aims to maximise the
number of clients immunised and the number of
completed courses of immunisation 
• improving treatment access, appropriateness and
effectiveness of treatment to women, people with
learning or physical disabilities, young people, minority
ethnic drug users, women, stimulant users and other
groups who may not be fully utilising the services.
All pharmacists will have standard operating procedures
(SOPs) in place specific to their individual premises.
All pharmacy services to drug users will have systems in
place to assess client satisfaction with the service.
Pharmacy service providers will ensure information is
available enabling locum pharmacists to continue to provide
the commissioned services.
2.11.1  Pharmacy needle exchange – policies and
protocols
The standard operating procedures for pharmacy 
needle exchange must detail requirements around 
the following issues:
• Security of staff, stock and premises
• Minimising risk to staff and members of the public
• Dealing with unacceptable behaviour and guidance on:
– what constitutes unacceptable behaviour 
– ways of minimising unacceptable behaviour.
• Seeking to prevent needle stick injuries
• Client confidentiality, including what to do when a 
patient requests needle exchange who is also being
prescribed substitute medication
• Dealing with needle stick injuries based on 
up-to-date information
• Dealing with spillage or contamination by potentially
infected blood or body fluids, or spillages of sharps
• Dealing with requests for needle exchange where the
pharmacist identifies an increased risk to an individual 
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for example, a client who is at risk of overdose, e.g.
recently released from prison, intoxicated and receiving
prescribed medication
• Ensuring all staff who may be involved in the service 
are instructed on procedures to be followed in order to
minimise risk
• How clients and members of the public can comment 
on the service, including making complaints
• What to do when a client under 18 requests needle
exchange. (Written polices and procedures as agreed
with the local area child protection committees, DATs 
and PCTs and PCOs.)
• Distribution of clean injecting equipment, personal sharps
containers, citric acid, ascorbic acid, water for injection
(ampoules of not more than 2ml volume) and other (legally
allowed) paraphernalia etc., including guidance on:
– whether there is a maximum number of syringes which
can be issued
– whether this is linked to the number of returns received
– local policies concerning secondary distribution of
equipment (i.e. clients collecting for other injectors)
– where injecting paraphernalia can be accessed by
clients if the whole range is not available from the
pharmacy scheme.
• Safe storage, disposal and destruction of used
equipment and clinical waste (in line with Environment
Agency requirements – note these are currently (Autumn
2005) being reviewed).
– The disposal of sharps is not included in the funding
from PCTs for the disposal of unwanted medicines 
– The Environment Agency will prosecute if it considers
the pharmacy causes pollution or harm to health when
storing or disposing of sharps.
• Advice and health promotion materials relating to 
harm reduction
• Information on other local harm reduction, needle
exchange and treatment facilities, including service 
user groups
• Advice on access to vaccination against hepatitis
A and B, relevant to both staff and clients
• Information, including contact details, on which
organisations at a local level are responsible for 
collecting drug litter 
• How to contact the scheme co-ordinator and 
what support and resources the pharmacy can 
expect from the scheme co-ordinator.
Pharmacy needle exchanges should have a written policy
on how to maximise the return of used equipment. This will
be decided at local level and could include actions such as
a target return rate agreed with the scheme co-ordinator
and a requirement for users to return equipment and
periodic awareness raising campaigns. This strategy should
be in line with Medicines, ethics and practice: a guide for
pharmacists (RPSGB, latest edition).
Scheme co-ordinators will engage local communities and
respond to their concerns in a proactive way – particularly
in response to discarded used injecting equipment.
2.11.2  Dispensing, supervised consumption and shared
care – policies and protocols
The NTA (2005) requires prescription services and
community pharmacies to have agreed systems and
procedures to provide appropriate dispensing and
supervision of consumption of controlled drugs. Pharmacists
can only provide supervised consumption and shared care
where there are clear channels of communication with
keyworkers and prescribers, and the pharmacist is included
as part of the shared care arrangements.
The standard operating procedure for the provision of
dispensing, shared care and supervised consumption
services for substitute medication should include:
• ensuring security of staff, stock and premises
• minimising risk to staff and members of the public
• storage and dispensing of medications in accordance
with current legislation e.g. the Misuse of Drugs
Regulations 2001 and the Medicines Act 1968
• the provision of supervised self-administration
procedures that are discreet and efficient, to ensure the
dignity of the client
• strategies and procedures for ensuring the dose has
been fully consumed; for example, 
– in the case of methadone oral mixture, patients should
be offered a drink of water and should speak after
swallowing their dose;
– in the case of buprenorphine a longer time will be
needed to allow dissolution of the tablets. Patients
should be offered a drink of water before taking their
dose. If local policies support pharmacists crushing
buprenorphine tablets (an unlicensed use of the
medicine) then the local policy and lines of
accountability should be clearly indicated in the
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policy/protocol. Pharmacists may need to take out
additional insurance to cover this procedure. (The NPA
will indemnify members provided they comply with the
NPA model protocol.) Procedures describing the
crushing of doses must be evidence based, fully
supported by the local shared care monitoring group,
the prescriber, clinical governance leads and informed
patient consent must be obtained. A risk assessment
must be made to minimise/ remove any risks to the
operator or patient as a result of crushing. (examples
of potential risks include danger from inhaling the
powder, danger from crushing the tablets too finely
can create a sludge that sticks to the buccal mucosa)
– what the pharmacist should do if s/he suspects the
patient is avoiding supervised consumption; for
example, by palming buprenorphine tablets, by holding
methadone mixture in the mouth and not swallowing.
• safe storage, disposal and destruction of clinical waste (in
line with Environment Agency requirements), for example
the containers used for administering supervised doses
• safe storage, disposal and destruction of items which
may identify patients, for example, labelled containers
which are discarded after supervised consumption
• dealing with unacceptable behaviour and guidance on:
– what constitutes unacceptable behaviour 
– ways of minimising unacceptable behaviour.
• the provision of locally developed and agreed guidance,
which includes information on other relevant services and
contact points, including service user groups
• the development of agreements on how and when any
relevant information will be shared between prescribers,
keyworkers, social workers and pharmacists
• guidance on what to do if a patient is intoxicated, is
showing signs of overdose or misses collecting doses
• guidance on what to do if the patient requests that their
prescribed medicine be collected by another person
• service user confidentiality, including what to do when 
a patient requests needle exchange and is also being
prescribed substitute medication
• the provision of guidance to patients, of those services
the pharmacy is legally able to provide, what restrictions
apply and why there are limitations
• advice and health promotion materials relating to
harm reduction
• advice and access to vaccination against hepatitis 
A and B
• how patients and members of the public can comment
on the service, including bringing complaints
• specifying which service users the standard operating
procedure includes and excludes. This will depend on
what pharmaceutical service is commissioned. For
examples, see section 2.4.2.2
• guidance on what the pharmacist should do when a
prescription or patient does not meet the agreed
inclusion criteria – for example, the pharmacist has not
been contacted by the prescriber or keyworker, or a
shared care agreement has not been provided, or a
patient’s prescription is from “out of area”
• guidance on what the pharmacist should do when an
expected patient does not appear at the pharmacy 
• how to contact the shared care or scheme co-ordinator
and what support and resources the pharmacist can
expect from the scheme co-ordinator.
2.12 Monitoring and review
Monitoring is an integral part of the contract or service
agreement and continuation or termination of the contract.
Information agreed between the commissioner and the
provider will be supplied to shared care and scheme 
co-ordinators, in accordance with the requirement stated 
in the service specification. Information may also be
required on issues not specified in this service specification,
including issues based on principles and arrangements of
clinical governance.
Where local milestones and targets are set to aid contract
monitoring, these are developed and agreed with pharmacy
service providers.
Service reviews are undertaken where and when required,
including those investigating client satisfaction of services.
The manner in which monitoring and review are undertaken
may vary from area to area. In some areas, the local PCT,
PCO or DAT may develop and agree milestones and
targets, whereas in others these may be agreed by the local
pharmaceutical committee (LPC) on behalf of all the
pharmacy contractors in the area.
Commissioners must ensure there is an up-to-date and
comprehensive list of pharmacy needle exchange outlets
and pharmacies providing dispensing, supervised
consumption and shared care, to avoid payment continuing
after pharmacies have closed down, moved premises or
withdrawn from the scheme. This is also important for
strategic planning for the service.
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2.13  Data collection and claims for payment
Data is collected in order to monitor the uptake of the
service, calculate key performance indicators and calculate
payments to the participating community pharmacies.
Information agreed between the commissioner and
providers will be supplied to the authorised officer in
accordance with the requirements stated in the service
specification. This should include:
• a minimum data set which must be collected (see below)
• how data should be collected, e.g. the forms to be used
• data confidentiality issues approved by Caldicott
Guardian of the PCT, PCO or NHS trust
• where data should be sent for processing
• when data should be submitted for processing.
Data collection should be standardised to ensure uniformity
across the scheme. The task force to review services for
drug misusers (Department of Health, 1996) recommends
the following key performance indicators for pharmacies
and pharmacy needle and syringe exchange schemes:




• Numbers of exchange packs given out per month
• Numbers of needles and syringes sold to drug misusers
per month
• Numbers of individuals using the service (by gender)
• Numbers of pharmacies prepared to provide facilities for
return of used equipment
• Return rates of used equipment 
• Costs per pack distributed.
Data collection may also include the number of client
contacts (i.e. visits) and the number of contacts per client
per year/per month.
The Department of Health and NTA are planning to issue
national guidance on the minimum data set to be collected
following the national needle exchange audit carried out 
in 2005.
Robust payment arrangements for participating pharmacies
must be agreed locally. (Also see Appendix 1: How
community pharmacies are paid, section 4.6).These include:
• what documentation will be used for informing
pharmacies how their payments are made (e.g. via the
Prescription Pricing Authority, cheque, BACS or local
PCT and PCO arrangements) and how they can be
individually identified (for example, not merged with other
enhanced service payments)
• how payments are calculated
• the frequency of payments (e.g. monthly, quarterly)
• who to contact concerning any payment queries
• specific arrangements for multiple pharmacy groups 
(e.g. individual branch payments may need to be sent 
to a central head office and clearly identify branch
number and the service being paid for)
• arrangements for auditing payments (including reference
numbers for payment tracking) 
• arrangements to identify and prevent fraudulent claims.
There must also be clear information on how to contact the
scheme co-ordinator and what support and resources the
pharmacy can expect from the scheme co-ordinator.
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3 Clarifying current and 
future roles for pharmacists in 
the provision of services to
substance users
Pharmacists, as part of a team of healthcare
professionals, have a key role to play in providing services
to substance users.
This section seeks to clarify the different levels of expertise
required in each area and the different roles played by
pharmacists in the different branches of the profession.
Although there are similarities to the medical practitioner
structure of generalist, specialised generalist, GP with
special interest and specialist, there are fundamental
differences. In particular, hospital pharmacists and PCT 
and PCO pharmacists will often have quite different – and
specific – roles and responsibilities.
To become a pharmacist, a Masters degree in pharmacy,
approved by the Royal Pharmaceutical Society of Great
Britain (RPSGB), is needed. After the four-year pharmacy
degree, graduates must spend a year in practical training in
community, hospital or industry and pass a pre-registration
exam before they can become registered with the RPSGB
and are allowed to work as a pharmacist. Often
pharmacists will study further to achieve a postgraduate
qualification, such as a clinical diploma.
3.1  The generalist: Level 1
Generalist6 pharmacists may be involved in the treatment 
of drug misuse although this is not their main area of work.
Appendix 2: Understanding the new pharmacy contract
explains mechanisms and ways in which commissioners
and DATs can help pharmacists, to ensure their core,
essential and advanced service provision includes
substance misusers.
A large number of pharmacists have already completed
substance misuse training through the Centre for Pharmacy
Postgraduate Education (CPPE) in England or the equivalent
training provided through the Scotland, Wales and Northern
Ireland centres. Pharmacists who have completed the CPPE
Substance misuse distance learning pack are eligible to
claim exemption from the Part 1 training of the Royal
College of General Practitioner’s (RCGP) certificate in the
management of drug misuse in primary care. These
pharmacists would be considered to be the pharmaceutical
equivalent of the generalist medical practitioner.
Some PCT and PCO pharmacists and some hospital
pharmacists will have also completed the CPPE distance
learning pack Opiate treatment: supporting pharmacists for
improved patient care.
3.2  The specialised generalist or PhwSI in
drug misuse: Level 2
A significant number of pharmacists who have obtained
exemption from the Part 1 RCGP certificate have gone on
to complete the Part 2 certificate and these are sometimes
referred to as pharmacists with a special interest (PhwSI) 
in drug misuse. However, the roles and responsibilities of
pharmacists with special interests are still (December 2005)
being defined. Some pharmacists who have completed 
the Part 2 certificate are developing their roles further, 
for example, by becoming supplementary prescribers. 
In addition, co-ordinators of pharmacy needle exchange
schemes and shared care schemes are often pharmacists
who have completed Part 2.
Pharmacists who have completed Part 2 are an untapped
resource with whom commissioners and DATs are
encouraged to make contact. Such pharmacists are well
suited for inclusion on shared care monitoring groups and
strategic discussions with PCTs, PCOs and local
pharmaceutical committees (LPCs), as often these groups
may not have any specific specialist knowledge of the
substance misuse field.
Specifically, such pharmacists can also help persuade 
other pharmacists to become involved in the work 
of needle exchange and supervised consumption, 
as often the preventing factor is isolation and a lack of
professional support.
Specialist generalist pharmacists can work in a number of
different settings for example, in community pharmacies,
hospital pharmacies, PCTs and PCOs, specialist drug
services and community drug teams.
27
6 Note: “generalist pharmacist” is not a term commonly used by the pharmaceutical profession. 
Best practice guidance for commissioners and providers of pharmaceutical services for drug users 
3.3  The consultant pharmacist: Level 3
In April 2005, the Department of Health produced 
guidance for the development of consultant pharmacist
posts. Posts are defined and developed based on local
need and structured around four main functions:
• expert practice
• research evaluation and service development
• education mentoring and overview of practice
• professional leadership
Specific strategic health authority panels approve such
posts, in the same way that consultant nurses or consultant
allied health professionals are approved and appointed.
3.4  Pharmacists as supplementary or
independent prescribers
Legislation relating to pharmacist prescribing is complex,
particularly in the field of substance misuse. Supplementary
prescribing, where a doctor (e.g. a psychiatrist or GPwSI)
undertakes an initial client assessment and then agrees 
a clinical management plan with the supplementary
prescriber, is particularly appropriate for the management 
of long-term conditions. One of its major benefits is
providing the opportunity for pharmacists (and nurses) to
jointly manage the prescribing responsibilities for patients
on long-term maintenance or detoxification programmes,
which is underpinned by robust local polices and
procedures. In practice, this should lead to better quality
prescribing and, as a result, improved treatment
effectiveness. (See Nurse prescribing in substance misuse
NTA May 2005 (further updates will include information 
on pharmacist prescribing) for more information about
supplementary and independent prescribing.) In November
2005, the Department of Health announced an extension to
the prescribing powers of pharmacists and nurses, allowing
them to become independent prescribers. This extension
does not include the prescribing of controlled drugs, 
but will allow appropriately trained nurses and pharmacists
to prescribe for other conditions.
Pharmacists (and nurses) will be able to undertake these
roles once they have successfully completed the relevant
training courses accredited by their respective regulatory
bodies and had these qualifications noted on the
professional register. Once trained, they will be required 
to keep their skills up to date. Employers will allow nurses
and pharmacists to prescribe once they are satisfied that
they have appropriate registration and have all the skills 
and competencies relevant to the clinical area where they
will be prescribing.
Pharmacist and nurse prescribers will have to work within
their employers’ clinical governance frameworks and they
will be accountable to both their employers and their
regulatory bodies for their actions. The RPSGB has
published a Clinical governance framework for pharmacist
prescribers and organisations commissioning or
participating in pharmacist prescribing (GB wide).
It is important that pharmacist (and nurse) prescribing
initiatives are developed within a clear strategic
managerial framework, which identifies the organisational
and support mechanisms necessary for implementation
and a clear vision of how pharmacist prescribing will
contribute to improved service delivery and patient care.
Commissioners will need specialist pharmaceutical advice
from hospital pharmacists or primary care trust
pharmacists concerning, for example, ordering of
prescription forms needed for use by supplementary and
independent prescribers, obtaining prescription data
analyses and producing prescribing formularies.
3.5  Pharmacists and patient group directions
Patient group directions (PGDs) are written instructions for
the supply and consumption of medicines to groups of
patients who may not be individually identified before
presentation for treatment. It is not a form of prescribing
and there is no specific training that health professionals
(e.g. pharmacists, nurses, occupational therapists) must
undertake before supplying medicines under a PGD,
although local training is usually given for specific PGDs.
Examples where PGDs can be used by pharmacists (and
nurses) to administer medicines, which would normally
require a prescription, are hepatitis A and B vaccination,
antibiotics, medicated dressings and one-off symptomatic
relief of opioid withdrawal. However, controlled drugs such
as methadone and buprenorphine cannot be administered
under a PGD.
A pharmacist must be included as part of the
multidisciplinary group producing any PGD, which must
then be ratified by the NHS trust, PCT or PCO.
For more information, refer to the RPSGB Fitness to
Practice and Legal Affairs Directorate Patient Group
Directions. A Resource Pack for Pharmacists (January 2004,
www.rpsgb.org.uk)
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3.6  Pharmacist roles in substance misuse
Generally, community pharmacists with an interest in drug
misuse, will usually provide needle and syringe exchange
services and dispensing services for drug users. They
would also provide treatment in the context of a shared
care scheme and provide supervised consumption.
Pharmacists are encouraged by the RPSGB to provide such
services only as part of a locally agreed scheme to ensure
consistent standards and integrated care. Where schemes
are not co-ordinated and managed in a way that adequately
supports the individual community pharmacist, pharmacists
may be reluctant to get involved. Pharmacists may be
willing to provide a service, but only if there is adequate
recompense for the time involved. (See Appendix 1: How
community pharmacists are paid).
However, there are many more areas where pharmacists
can, and do, contribute to the wider field of substance
misuse work in prevention, harm minimisation and
treatment as well as helping retain people in treatment.
These may not necessarily be in the community pharmacy
setting and include:7
• provision of smoking cessation services
• signposting to other services
• health promotion and health education




• treatment of overdose
• detection and management of solvent misuse
• over-the-counter medicines
• brief alcohol interventions
• emergency hormonal contraception
• advice about and testing for sexually transmitted
infections (e.g. chlamydia)
• providing hepatitis A and B immunisation under, for
example, a patient group direction
• wound care
• checking injection sites.
Some of these areas of development have been made
possible as a result of changes in legislation and the
changing context in which healthcare is being delivered to
the population, including:
• the extension of prescribing rights and supplementary
prescribing by pharmacists – which includes (from April
2005) controlled drugs
• the new community pharmacy contract
• the use of information technology to enhance service
provision
• UK-wide developments, such as the recommendations
flowing from the Shipman Inquiry.
Commissioners and DATs are encouraged to liaise with
community pharmacists, either through the local
pharmaceutical committee (LPC) or PCT and PCO
pharmaceutical advisers, so that drug users in the
community can access and gain maximum benefit from
services, which are available from the community
pharmacist which they are entitled to receive.
3.7  PCT and PCO pharmacists
PCT and PCO pharmacists, such as pharmaceutical
advisers or chief pharmacists for these organisations, are
key people for commissioners to liaise with, as generally
they will be directly involved in commissioning other services
from pharmacists and will have established links with the
LPC, community pharmacists and hospital pharmacists. In
addition, they will also be involved in activities such as
writing patient group directions, procedures and protocols,
contracts, and analysing prescription data.
3.8  Hospital pharmacy services
It is important for commissioners to understand that
hospital pharmacists have no managerial responsibility for
community pharmacists. However, they will regularly liaise
with PCT and PCO pharmaceutical advisers and will often
provide advice and information to community pharmacists.
Not all hospitals will have pharmacists with a special
interest in substance misuse. Commissioners and DATs
should work with NHS trusts to ensure that pharmaceutical
care of drug users is maintained when patients are under
the care of the secondary care team, for example when
drug users are admitted into hospital via A&E or for planned
procedures.
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3.8.1  Specialist mental health pharmacists
Hospital pharmacists working in mental health trusts may
work with the specialist substance misuse teams. It is
important for commissioners to ensure that pharmaceutical
services are included either as direct costs or as on-costs
for specialist services.
Pharmacists’ responsibilities include but are not limited to:
• contributing to risk reduction by supporting safe
medication practice
• participating in multidisciplinary patient reviews
• providing prescribing and pharmaceutical advice and
medicines information
• medicines management training for medical, nursing and
other staff
• drug interactions with methadone, buprenorphine and
other medications
• running titration clinics
• developing clinical audits to qualitatively monitor 
and review drug use across the service, to reduce
prescribing risks
• public health and health promotion
• ensuring medicines are used safely
• advising on safe and secure storage of controlled drugs,
including working with local police and nursing staff
concerning procedures for dealing with illicit substances
brought in by patients and visitors
• providing clinical pharmacy services to inpatients
undergoing substance misuse treatment
• developing and writing treatment guidelines, procedures
and protocols
• developing and writing patient group directions
• writing and providing patient information leaflets
• working with service users, looking at their medicines 
and managing medication
• contributing to the clinical governance agenda
• monitoring prescribing and prescriptions, including
adverse drug reactions and avoiding drug interactions
• ensuring staff comply with legal and professional
requirements
• analysing prescribing data, e.g. from the Prescription
Pricing Authority
• providing medicines information and advice to clinicians
and other staff for example, use of drugs in pregnancy,
drug interactions 
• working with the substance misuse services:
– dispensing and providing supervised consumption of
prescribed medicines
– providing needle exchange services
– advising on prescription storage, handling, writing and
automatic prescription writing software systems.
In addition, their specialist psychiatric pharmacy knowledge
ideally places them to run specialist groups for, for example,
patients treated for mental health problems that may use
illicit drugs, for example bipolar patients who use cannabis.
Pharmacists working with a specialist community drugs
team will often be employed as part of the hospital
pharmacy service to ensure clinical governance, CPD and
professional support is provided.
For outpatient populations, the hospital pharmacist has a
role in communicating and liaising with hospital, community
and primary care professionals.
3.8.2  Acute hospital pharmacists
Hospital pharmacists in acute trusts have specific roles and
responsibilities:
• Ensuring pharmaceutical care of patients on substitute
prescribing programmes continues on admission to
hospital, for example, ensuring treatment is not curtailed
due to a lack of understanding and acceptance of the
substitute prescribing programme by hospital-based staff
• Ensuring that patients admitted into hospital do not have
inappropriate discontinuation or disruption of substitute
medication which can result in early discharge from
secondary care and a return to the use of street drugs
• Ensuring adequate pain relief
• Providing advice on the practicalities of issuing
instructions to nursing staff when controlled drugs are
being prescribed 
• Hospital-based medicines information pharmacists may
also play an important role in advising both community
and secondary care colleagues on treatment regimens,
providing written information and literature research, as
well as assisting in the identification of tablets following
accidental poisoning.
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3.9  Pharmacy technicians
Pharmacy technicians work in both community and
hospital pharmacies and work under the supervision of
qualified pharmacists. Senior technicians train and
supervise junior staff.
To qualify as a pharmacy technician requires an NVQ Level
3 in pharmacy services. The training involves both practical
experience and study at a college or by open learning and
takes about two years to complete.
Pharmacy technicians working under the supervision of the
pharmacist will:
• manage all aspects of supply and dispensing of
medicines
• support management of the dispensary
• provide final accuracy checking of prescriptions
• provide supervision of pharmacy assistants
• provide client advice and education for compliance 
with medication
• store medicines properly and securely
• participate and assist in clinical audit
• assist with modernisation of pharmacy computer systems
including automation and prescribing software
programmes 
• keep records, order stock and check expiry dates 
of drugs.
As the clinical role of the pharmacist expands, pharmacy
technicians are becoming more involved in substance
misuse work, for example, assisting the pharmacist with
providing supervised consumption and needle exchange.
The Centre for Pharmacy Postgraduate Education (CPPE) 
is currently producing an open learning training pack
specifically aimed at pharmacy technicians working in the
field of substance misuse.
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4 Sample schedules
All contract and service level agreements must include a
series of schedules. The schedules may vary according 
to local contracting arrangements and should be developed 
at local levels with (where relevant) the primary care
organisation (PCO), NHS trust, local pharmaceutical
committee (LPC), and relevant departments of
commissioning organisations.
The manner in which decisions regarding local negotiations
are made at present may vary from area to area. In some
areas, the local pharmaceutical committee will negotiate
with the PCT, PCO or DAT on behalf of all the pharmacy
contractors in an area, in others the local PCT, PCO or DAT
will negotiate with individual pharmacies.
However, it is recommended that the information outlined
below be identified prominently in the contract or service
level agreement.
4.1  Schedule 1: The care service
The care services are the provision of pharmaceutical
services for drug users aged 18 years and over, who access
the services of the provider. The care services are to be
delivered in accordance with the standards detailed in the
service specification.
The anticipated capacity level of the care service should be
included in the schedule.
4.2  Schedule 2: The providers and project
locations
(For services commissioned from a community pharmacy.)
The providers will be individual community pharmacies, e.g.
Any Pharmacy Ltd whose registered address is at:
Somewhere pharmacy, Any Road, Any Town XX1 2YY
Arrangements will need to be in place for pharmacies
outside the drug action team or primary care organisation
area. Patients may choose to have their prescription
dispensed elsewhere – a pharmacy will not provide a
supervised consumption service unless the service has
been commissioned.
For services commissioned from a secondary care trust:
The provider organisation’s legal title, registered office or
place of business, and the address of the project should 
be included here.
4.3  Schedule 3: Contract period and
payment procedures
The contract period will be determined locally by
negotiation between, for example, the local pharmaceutical
committee (LPC) and the primary care organisation, subject
to the terms of the contract and the monitoring
requirements stated in the service specification.
The manner in which the contracted fees are paid will be
determined locally, for example, by negotiation with the
local pharmaceutical committee or the primary care
organisation, subject, where appropriate, to the submission
of activity data on the agreed proforma.
4.4  Schedule 4: Monitoring requirements
Monitoring requirements based on the service
specifications and any other locally determined
requirements may be included.
4.5  Schedule 5: Responsible officers
This section should include details of the authorised officer
from the commissioning body (i.e. primary care trusts and
primary care organisation) and the contract manager from
the service provider.
The authorised officer for [Any PCT or PCO] under the
contract is:
Name: John Anybody
Designation: Commissioning director, primary care
director, chief pharmacist or prescribing
advisor
Location: Any PCT/PCO / Address of PCT/PCO
Telephone no:
The contract manager for [Any Pharmacy] is:
Name:
Designation: In some cases this may be a national,
regional or area manager (e.g. in the
case of multiple pharmacies)
Location: Address of pharmacy
Telephone no:
Reference – PSNC guide on SLAs –
www.psnc.org.uk/resources/publications
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5 Appendix 1: How community
pharmacies are paid
5.1  NHS community pharmacy contract
Community pharmacies are independent contractors, who
offer NHS services, in a similar way to GPs, dentists and
optometrists. They hold a ”contract”8 with the local primary
care trust or ogranisation (PCT or PCO).
The current (from April 2005) national contractual framework
requires pharmacies to dispense NHS prescriptions and
operate a repeat dispensing service. It also requires them to
provide self-care advice and support to people with self-
limiting conditions such as coughs, colds and minor skin
complaints. Pharmacists and their staff will also refer people
to other sources of help within the local health and social
care community, including to the voluntary sector.
Community pharmacies offer healthy lifestyle advice to
certain defined groups of patients, including those who
smoke, and they are also expected to take part in up to six
PCT or PCO-organised health promotion campaigns each
year. The contract also requires them to collect unwanted
medicines from the public, for safe disposal (but not sharps
and clinical waste) and to operate within a clinical
governance framework. Pharmacists must also operate
within the requirements of the Medicines Act and the
Misuse of Drugs Act and its regulations. These services are
all part of the essential tier of the contract that all pharmacy
contractors must provide (see Appendix 2 for more details
about the new pharmacy contract).
5.2  Payments to community pharmacies
Pharmacy contractors are not paid a salary by the PCTs,
PCOs or the NHS. However, in return for providing NHS
services, community pharmacy contractors are paid a
number of nationally agreed fees and allowances. These
fund the costs of provision of NHS community pharmacy
services and provide a fair return for the contractor. Details
of the national fees and allowances are contained in the
current edition of the Drug Tariff (see www.ppa.nhs.uk). 
In the case of FP10MDA (instalment prescriptions), each
prescription requires multiple dispensing (commonly 12 
for a 14-day prescription). For each prescription, the
pharmacist must dispense the item 12 times into 12
containers, resulting in 12 dispensing fees, 12 practice
payments and 12 container allowances. In addition,
controlled drugs such as methadone or buprenorphine 
require special storage and recording, resulting in 12
controlled drug (CD) fees. (NB: the CD fee for methadone is
higher than for buprenorphine.) There is also reimbursement
for the cost of the drug supplied.
These nationally agreed payments are determined by taking
into account the cost of the pharmacist’s time and also all
the costs incurred in running the business (for example,
heating, lighting, business rates, salaries and employing
staff, telephone, fax and computer costs).
Any extra work, which a community pharmacy undertakes
over and above the core requirements of the contract,
incurs additional costs. For example, shared care requires
more time per patient and may involve extra telephone calls
and a greater level of record keeping. Similarly, needle
exchange and supervised consumption require additional
time, additional storage space for equipment and additional
training time for all staff members. Any costs for special
fixtures such as CCTV, private areas or extra controlled drug
cabinets are additional costs that have to be resourced. 
It is therefore vital that commissioners clarify what
additional services are being commissioned, together with
the inclusion and exclusion criteria and ensure these criteria
are clearly communicated to other service providers who
expect to work with community pharmacies.
At the end of each month, pharmacies send all NHS
prescriptions dispensed to the Prescription Pricing Authority
(PPA). The PPA prices the prescriptions by calculating the
costs of the medicines and appliances dispensed.
Pharmacies are then paid these costs together with the
national fees and allowances, less any NHS prescription
charges collected by the pharmacy from patients. The costs
of some of these fees and allowances are charged back to
PCTs and PCOs and in some circumstances to secondary
care trusts. This is dependent on whether the prescription 
is generated in primary or secondary care. Commissioners
and secondary care specialist service budget holders are
encouraged to discuss the difference in fee structure with
hospital and PCT and PCO chief pharmacists, especially 
if new prescribing services are being planned.
The community pharmacy receives the same nationally
agreed NHS payments irrespective of where the
prescription originates.
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These payments do not include payment for supervised
consumption or shared care.
A number of secondary care substance misuse services
have worked to reduce costs by arranging in-house
dispensing or setting up an outpatient-style supervised
consumption arrangement. It is important when calculating
secondary care in-house dispensing costs that costs such
as staff time, equipment, heating lighting, enhanced
security, insurance and VAT are all included to ensure the
true cost of the service is established.
5.3  VAT
Some locally commissioned services, such as needle and
syringe exchange services, can sometimes be subject to
VAT. Historically, there has been some degree of variation
across the country in the way HM Revenue & Customs
have treated similar schemes – sometimes they were VAT
exempt and sometimes VAT had to be paid by the
commissioner. Attempts are ongoing to obtain clarity on this
issue at a national level – however commissioners should
be aware of the potential that VAT may have to be paid
when needle exchange services are commissioned. In some
cases it may be possible to reclaim some of the VAT paid,
for example, VAT charged on pack preparation. VAT should
not be seen as a barrier to commissioning.
Community pharmacies are able to reclaim VAT paid on
medicines they supply on prescriptions from doctors or
dentists. However, hospital pharmacies are unable to
reclaim VAT on the medicines they purchase and dispense.
5.4  Payment issues
A single DAT or commissioner may be dealing with many
pharmacies across a locality. It will be necessary to have
payment arrangements in place that are simple to
administer and provide a regular reporting mechanism 
for individual pharmacies to check how payments have
been calculated.
Where payments are made locally, as with enhanced
services, a community pharmacy will generally be paid
irrespective of where the prescription originates. This should
be confirmed locally with the pharmacy contractors, local
pharmaceutical committee (LPC), PCTs and PCOs, so that
pharmacies will be assured of payment (and ensure
pharmacies are not paid twice). For example, if they are
commissioned to provide supervised consumption for
patients, this should include those patients whose
prescription has been written by a prescriber outside the
DAT, PCT or PCO area. Commissioners should bear in mind
the following:
• The Prescription Pricing Authority can process payment
for some services on behalf of commissioning agencies
• Some NHS areas have shared contractor management
agencies that manage local relationships with primary
care contractors and process local payments for these
contractors. These agencies may be able to offer this
service to DAT commissioners
• Payments will normally need to be made to the individual
pharmacy contractor. In the case of multiple pharmacy
groups, payments may be made to individual pharmacies
by arrangement if their branches normally operate as
individual business units
• Multiple pharmacy groups may require payment details to
be available to their head offices and regional managers,
in order to check payments have been made
• Remittance advice notes accompanying payments need
to clearly explain what the payment is for and specify
individual branch numbers in the case of multiple
pharmacy groups
• Pharmacy contractors need to understand how payments
have been calculated and know in advance what
payment to expect
• Pharmacies and commissioners need to clarify in
advance (for example through service level agreements
which are reflected in the standard operating
procedures) what services the pharmacist is expected to
provide and for which service users, namely inclusion
and exclusion criteria
• Pharmacies should be provided with a single point of
contact who can deal with all payment queries
• Any payment claim system must also have a system for
validation of the claim to prevent fraud (advice can be
obtained from local NHS counter fraud professionals)
• A system needs to be in place for notification of changes
of ownership of pharmacies
• BACS payments are preferred by many pharmacies
(where PPA payment systems cannot be used), but again
systems need to be in place to ensure changes in
ownership and bank accounts are communicated 
• Payment claims and receipts must be available for audit
by both commissioners and community pharmacy
contractors.
• See section 6.4: Enhanced services for an explanation of
how payment fees will be calculated.
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6 Appendix 2: Understanding the
new pharmacy contract
6.1  Contracted services available from
community pharmacies
The new contract aims to provide clear minimum standards
for pharmacies, reward high-quality services and make
better use of the skills of pharmacists and pharmacy staff.





Implementation of the new contract is being phased over
time. Essential services will be provided from 1 April 2005,
but pharmacy contractors do not have to comply with all
the requirements until October 2005. Advanced services are
being introduced during 2005/06 and the first enhanced
services will probably be commissioned from April 2006 –
however pre-existing locally commissioned services are
likely to continue during 2005/06. Some primary care
organisations (PCTs and PCOs) are already commissioning
local enhanced services.
Pharmacy contractors are paid according to the services
they provide. Essential services are mandatory, however
advanced services and locally commissioned enhanced
services are two optional tiers of service provision.
Pharmacists who have completed certain training and work
in pharmacies that have particular facilities are able to
provide advanced services.
The enhanced services are locally commissioned by PCTs
and PCOs in response to local health priorities. The local
PCT and PCO decides which of the enhanced services are
required in a particular area and can appoint one or more
pharmacies to provide them. To allow equal opportunity 
for all community pharmacies to take part, the service must
be offered to all pharmacies in the specified locality –
commissioners, PCTs and PCOs must not select them. 
The services may be based upon nationally produced
service specifications, or designed and negotiated with
local pharmaceutical committees (LPCs), PCTs and PCOs
at a local level. The nationally agreed enhanced services list
includes specifications for a needle and syringe exchange
scheme (Appendix 3) and a supervised consumption
scheme (Appendix 4).
6.2  Essential services offered by all
pharmacy contractors
There are seven essential services, which all pharmacies 
will be paid for providing. These are:
• dispensing, including support for people with disabilities
• repeat dispensing
• disposal of unwanted medicines
• promotion of healthy lifestyles (public health)
• signposting
• support for self care
• clinical governance.
DATs are encouraged to work with PCTs and PCOs to
maximise the opportunities of those essential services
which could benefit substance misusers. For instance:
• Promotion of healthy lifestyles requires pharmacists to
provide brief (one to two minutes), opportunistic one-to-
one advice on healthy lifestyle topics such as smoking
cessation to certain patient groups that present
prescriptions for dispensing. In addition, pharmacists are
required to be involved in six local campaigns annually,
organised by PCTs and PCOs. For example, DATs may
be able to initiate a local campaign on hepatitis B
vaccination, nutrition and prevention of blood-borne
viruses, by working with PCTs and PCOs to disseminate
information via community pharmacies.
• Signposting patients to other healthcare providers.
Pharmacists and staff refer patients to other care
providers when appropriate. For example, DATs may work
with PCTs and PCOs to provide literature to community
pharmacies on local substance misuse services.
• Support for self-care. The provision of advice and
support by pharmacy staff to enable people to derive
maximum benefit from caring for themselves or their
families. The service will initially focus on self-limiting
illnesses, but support for people with long-term
conditions is also a feature of the service. For example,
DATs may work with PCTs and PCOs to work with
pharmacists to enable patients on substitute
prescriptions to access advice and treatment for self-
limiting conditions and minor ailments.
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6.3  Advanced services requiring accreditation
of the pharmacist and pharmacy
Pharmacists must pass a competency assessment 
before they can provide advanced services.
Currently, there is only one advanced service available – 
the medicines use review and prescription intervention
service – although more will evolve over time.
• The medicines use review involves the pharmacist
reviewing the patient’s medication, identifying 
any problems and then feeding back to the 
prescriber. The patient also receives a copy of the 
review report. This is usually conducted on a regular 
(e.g. annual) basis. These must only be provided 
for patients who have been using the pharmacy 
for the dispensing of their prescriptions for the 
previous three months
• The prescription intervention service is similar to a
medicines use review, except that it is triggered by a
significant problem with a patient’s prescription, which
would be over and above the basic interventions, relating
to safety, which a pharmacist would make as part of the
essential level dispensing service. Again, suggestions 
are fed back to the GP.
It is up to the pharmacist to decide which patients receive
this service. However, PCTs and PCOs are able to
recommend that pharmacists concentrate on specific
groups of patients. DATs are encouraged to work with PCTs
and PCOs to ensure this service is available to patients on
methadone and buprenorphine together with other
medications, such as anti-retrovirals, anti-tuberculosis
drugs, ritonavir and psychotropics.
Reviews must be conducted in a consultation area, which
ensures patient confidentiality. Such an area would also be
suitable for providing needle exchange and supervised
consumption of medicines.
Once accredited, pharmacists will be able to provide
medicines use reviews or prescription intervention service
for up to 200 patients in the first year.
6.4  Enhanced services
Each PCT and PCO may commission individual pharmacies
to provide particular enhanced services, depending on the
specific needs in each local area. These services may
include the following:
• minor ailments management
• stop smoking services
• needle exchange schemes
• supervised consumption of prescribed medicines
• supplementary prescribing.
See Appendix 3 for the service specification for needle
exchange, Appendix 4 for the service specification for
supervised consumption of prescribed medicines and
Appendix 5 for the service specification for supplementary
prescribing by pharmacists.
The enhanced services are locally commissioned by PCT
and PCOs in response to local health priorities. As with the
nGMS contract, these services are not mandatory. Services
can be based on:
• nationally produced service specifications. Work has
been ongoing to seek to agree benchmark prices but
after meetings between the PSNC, NHS Confederation
and Department of Health, it appears that a better
approach is the publication of a pricing toolkit. The PSNC
are currently (December 2005) developing a jointly agreed
toolkit for pricing, which will identify the elements to be
considered in pricing the service at a local level.
• locally designed and negotiated with local pharmaceutical
committees (LPCs) at a local level. These are similar to
local enhanced services.
Local contractual arrangements offer more flexibility in the
models of provision and financial payment. These may be
useful for maintaining the status quo in areas where local
arrangements are working.
The local shared care monitoring groups (SCMGs) have
responsibility for the monitoring of local shared care
arrangements, including supervised consumption of
substitute medication. This should continue.
Local joint commissioning groups, PCTs and PCOs
interested in the prevalence of blood-borne viruses should
contact the Health Protection Agency, which monitors their
incidence and prevalence in the UK.
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6.5  NTA recommendations
The NTA recommendations on Drug treatment and the new
GMS contract (2003) are equally applicable to the new
pharmacy contract:
• Joint commissioners, on behalf of local drug action
teams (DATs), should undertake brief reviews of local
arrangements for shared care and commission or
recommission pharmacy shared care schemes, using a
mixture of nationally enhanced service and locally
enhanced service contracts according to local needs.
• Future commissioning of primary care services should
aim to increase the quantity and quality of primary care
provision. Such increases should not lead to a
destabilising of current local drug treatment provision,
either through disinvestment in primary or secondary 
care services.
• Where shared care monitoring groups (SCMGs) exist and
are working effectively, they should continue to have
responsibility for monitoring local shared care
arrangements and advise joint commissioning groups on
the most appropriate contractual arrangements.
• In areas that do not have effective SCMGs, they should
be developed and include the appropriate membership
as outlined in Department of Health guidelines. (i.e.
including pharmacists and LPC representation).
• Local areas, via their SCMGs and joint commissioners,
should continue to ensure that pharmacists and
pharmacies involved in shared care schemes are
increased and maintained at a level appropriate for local
need and this proportion is made explicit for planning
purposes. In many areas, the Department of Health
target to have 30 per cent of GPs involved in shared 
care has been built into local delivery plans. Although 
no target has been set for pharmacy involvement, 
there needs to be sufficient to support this proportion 
of GPs as well as others, for example specialist
prescribers and DIP prescribers. This document
recommends that the eventual aim should be for the
majority (over 75 per cent) of community pharmacies to
provide dispensing, supervised consumption and shared
care, so that individual patients have maximum choice on
where to have their prescription dispensed. In addition,
the aim should be that a significant proportion (over 25
per cent) provide needle exchange, distributed
appropriately across the DAT, PCT and PCO localities.
• Where pharmacy services are negotiated locally,
payments should be the same within that DAT area 
for comparable services and should not vary between
primary care trusts (PCTs and PCOs). Differential
payments could lead to a postcode lottery of primary
care service within the DAT area, where differing 
PCTs and PCOs adopt different pay structures for
pharmacists.
• Primary and secondary care should work together 
in collaborative partnerships within integrated care
pathways to best meet the needs of drug users. 
The pharmacy contract implementation should
complement rather than disrupt Models of care
implementation.
• Shared care should be supported by a mixture of
mainstream health money (via PCTs and PCOs) and drug
treatment pooled treatment budget with payment linked
to the level and quality of treatment activity.
• Drug treatment services in primary care should be
underpinned by robust service level agreements with 
the primary care trusts, which have responsibility for
service provision.
• Whatever local arrangements are agreed, decision
making should go through the normal joint
commissioning group and be agreed with NTA regional
teams in the context of the drug treatment planning
process.
More details on the contract can be obtained from
www.psnc.org.uk/contract.
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8 Appendix 3: NHS community
pharmacy contractual framework
enhanced service – needle and
syringe exchange
1 Service description
1.1 Pharmacies will provide access to sterile needles 
and syringes, and sharps containers for return of used
equipment. Where agreed locally, associated
materials, for example condoms, citric acid and
swabs, to promote safe injecting practice and reduce
transmission of infections by substance misusers will
be provided.
1.2 Pharmacies will offer a user-friendly, non-judgmental,
client-centred and confidential service.
1.3 Used equipment is normally returned by the service
user for safe disposal.
1.4 The service user will be provided with appropriate
health promotion materials.
1.5 The pharmacy will provide support and advice to the
user, including referral to other health and social care
professionals and specialist drug and alcohol
treatment services where appropriate.
1.6 The pharmacy will promote safe practice to the user,
including advice on sexual health and STIs, HIV and
hepatitis C transmission and hepatitis B immunisation.
2 Aims and intended service outcomes
2.1 To assist the service users to remain healthy until they
are ready and willing to cease injecting and ultimately
achieve a drug-free life with appropriate support
2.2 To protect health and reduce the rate of blood-borne
infections and drug related deaths among service
users:
• by reducing the rate of sharing and other high risk
injecting behaviours
• by providing sterile injecting equipment and other support
• by promoting safer injecting practices
• by providing and reinforcing harm reduction messages
including safe sex advice and advice on overdose
prevention (e.g. risks of poly-drug use and alcohol use).
2.3 To improve the health of local communities by
preventing the spread of blood-borne infections by
ensuring the safe disposal of used injecting equipment.
2.4 To help service users access treatment by offering
referral to specialist drug and alcohol treatment
centres and health and social care professionals
where appropriate.
2.5 To aim to maximise the access and retention of all
injectors, especially the highly socially excluded.
2.6 To help service users access other health and social
care and to act as a gateway to other services (e.g. key
working, prescribing, hepatitis B immunisation,
hepatitis and HIV screening, primary care services etc).
3 Service outline
3.1 The part of the pharmacy used for provision of the
service provides a sufficient level of privacy and safety
and meets other locally agreed criteria.
3.2 The pharmacy contractor has a duty to ensure that
pharmacists and staff involved in the provision of the
service have relevant knowledge and are appropriately
trained in the operation of the service.
3.3 The pharmacy contractor has a duty to ensure that
pharmacists and staff involved in the provision of the
service are aware of and operate within local
protocols.
3.4 The pharmacy will allocate a safe place to store
equipment and returns for safe onward disposal. 
The storage containers provided by the PCO
commissioned clinical waste disposal service will be
used to store returned used equipment.
3.5 The pharmacy contractor should ensure that their staff
are made aware of the risk associated with the
handling of returned used equipment and the correct
procedures used to minimise those risks. A needle
stick injury procedure should be in place.
3.6 The pharmacy should maintain appropriate records to
ensure effective ongoing service delivery and audit.
3.7 Appropriate protective equipment, including gloves,
overalls and materials to deal with spillages, should be
readily available close to the storage site.
3.8 The pharmacy should clearly display the national
scheme logo or a local logo indicating participation in
the service.
3.9 Staff involved in the delivery of this service should be
offered immunisation for Hepatitis B.
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3.10 Pharmacists will share relevant information with other
healthcare professionals and agencies, in line with
locally determined confidentiality arrangements.
3.11 The PCO should arrange at least one contractor
meeting per year to promote service development and
update the knowledge of pharmacy staff.
3.12 The PCO will provide the exchange packs and
associated materials and will commission a clinical
waste disposal service for each participating
pharmacy. The frequency of waste collection should
be agreed to ensure there is not an unacceptable build
up of clinical waste on the pharmacy premises.
3.13 The PCO will need to provide a framework for the
recording of relevant service information for the
purposes of audit and the claiming of payment.
3.14 The PCO will need to provide details of relevant
referral points which pharmacy staff can use to
signpost service users who require further assistance.
3.15 The PCO should consider obtaining or producing
health promotion material relevant to the service users
and making this available to pharmacies.
4 Suggested quality indicators
4.1 The pharmacy has appropriate PCO provided health
promotion material available for the user group and
promotes its uptake.
4.2 The pharmacy reviews its standard operating
procedures and the referral pathways for the service
on an annual basis.
4.3 The pharmacy can demonstrate that pharmacists and
staff involved in the provision of the service have
undertaken CPD relevant to this service.
4.4 The pharmacy can demonstrate that the rate of return
of used equipment meets locally agreed targets.
4.5 The pharmacy participates in an annual PCO
organised audit of service provision.
4.6 The pharmacy co-operates with any locally agreed
PCO-led assessment of service user experience.
Background information – not part of the service
specification
The National Treatment Agency for Substance Misuse
service specification for Needle Exchange and Harm
Reduction sets out a series of objectives for needle
exchange services generally, these apply to services
commissioned from community pharmacy and are reflected
within the service specification:
• To offer user-friendly, non-judgmental, client-centred and
confidential services
• To assist the service users to remain healthy until they are
ready and willing to cease injecting and ultimately achieve
a drug-free life with appropriate support
• To reduce the rate of sharing and other high risk injecting
behaviours by providing sterile injecting equipment and
other support
• To reduce the rate of blood-borne infections among drug
users
• To reduce drug-related deaths (immediate death through
overdose and long-term such as blood borne infections)
• To promote safer injecting practices
• To provide focused harm reduction advice and initiatives,
including advice on overdose prevention (e.g. risks of
poly-drug use and alcohol use)
• To provide and reinforce harm reduction messages
• To help service users access drug treatment to refer to
other specialist drug (and alcohol) treatment services
• To help service users access other health and social care
and to act as a gateway to other services (e.g. key
working, prescribing, hepatitis B immunisation, hepatitis
and HIV screening, primary care services etc)
• To facilitate access to primary care where relevant
• To ensure the safe disposal of used injecting equipment
• To prevent initiation into injecting and to encourage
alternatives to injecting
• To aim to maximise the access and retention of all
injectors, especially the highly socially excluded, through
the low-threshold nature of service delivery and
interventions provided
• To improve the health of local communities by preventing
the spread of blood-borne viruses and by reducing the
rate of discarded used injecting equipment.
There is good evidence that community pharmacy based
needle exchange services can complement and support
other needle exchange and harm minimisation initiatives
commissioned by drug treatment agencies.
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Background information for drug action team
commissioners:
Service Specification Tier (2 or 3), Pharmaceutical Services
for Drug Users,
National Treatment Agency for Substance Misuse, 2005,
www.nta.nhs.uk
CPPE training which may support this service:
Opiate treatment: Supporting pharmacists for improved
patient care open learning Public Health – drug users, 
harm reduction workshop
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9 Appendix 4: NHS community
pharmacy contractual framework




1.1 This service will require the pharmacist to supervise
the consumption of prescribed medicines at the point
of dispensing in the pharmacy, ensuring that the dose
has been administered to the patient
1.2 Pharmacies will offer a user-friendly, non-judgmental,
client-centred and confidential service
1.3 The pharmacy will provide support and advice to the
patient, including referral to primary care or specialist
centres where appropriate
1.4 Examples of medicines which may have consumption
supervised include methadone and other medicines
used for the management of opiate dependence, and
medicines used for the management of mental health
conditions or tuberculosis.
2 Aims and intended service outcomes
2.1 To ensure compliance with the agreed treatment 
plan by:
• dispensing in specified instalments1 (doses may be
dispensed for the patient to take away to cover days
when the pharmacy is closed)
• ensuring each supervised dose is correctly consumed
by the patient for whom it was intended.
2.2 To reduce the risk to local communities of:
• overuse or underuse of medicines
• diversion of prescribed medicines onto the illicit 
drugs market
• accidental exposure to the supervised medicines.
2.3 To provide service users with regular contact with
healthcare professionals and to help them access
further advice or assistance. The service user will be
referred to specialist treatment centres or other health
and social care professionals where appropriate.
3 Service outline
3.1 The part of the pharmacy used for provision of the
service provides a sufficient level of privacy and safety
and meets other locally agreed criteria.
3.2 The pharmacy will present the medicine to the service
user in a suitable receptacle and will provide the service
user with water to facilitate administration and/or
reduce the risk of doses being held in the mouth.
3.3 Terms of agreement are set up between the prescriber,
pharmacist and patient (a three-way agreement) to
agree how the service will operate, what constitutes
acceptable behaviour by the client, and what action
will be taken by the GP and pharmacist if the user
does not comply with the agreement. A “four-way”
agreement could also be developed which would
include the specialist centre.
3.4 The pharmacy contractor has a duty to ensure that
pharmacists and staff involved in the provision of the
service have relevant knowledge and are appropriately
trained in the operation of the service.
3.5 The pharmacy contractor has a duty to ensure
that pharmacists and staff involved in the provision 
of the service are aware of and operate within local
protocols.
3.6 The pharmacy should maintain appropriate records to
ensure effective ongoing service delivery and audit.
3.7 Pharmacists will share relevant information with other
healthcare professionals and agencies, in line with
locally determined confidentiality arrangements.
In this service specification it is assumed that instalment
dispensing is provided for by the provisions of the
dispensing or repeat dispensing essential services. If this 
is not the case for a particular medicine which may be
included in the service, local arrangements will need 
to be developed.
3.8 The PCO should arrange at least one contractor
meeting per year to promote service development and
update the knowledge of pharmacy staff
3.9 The PCO will need to provide a framework for the
recording of relevant service information for the
purposes of audit and the claiming of payment
3.10 The PCO will need to provide details of relevant
referral points which pharmacy staff can use to
signpost service users who require further assistance
3.11 The PCO should consider obtaining or producing
health promotion material relevant to the service users
and making this available to pharmacies
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4 Suggested quality indicators 
4.1 The pharmacy has appropriate PCO provided health
promotion material available for the user group and
promotes its uptake
4.2 The pharmacy reviews its standard operating
procedures and the referral pathways for the service
on an annual basis
4.3 The pharmacy can demonstrate that pharmacists and
staff involved in the provision of the service have
undertaken CPD relevant to this service
4.4 The pharmacy participates in an annual PCO
organised audit of service provision
4.5 The pharmacy co-operates with any locally agreed
PCO-led assessment of service user experience
Background information
(not part of the service specification)
Current guidelines2 recommend all new treatment of opiate
dependence be subject to supervised consumption for the
first three months or a period considered appropriate by the
prescriber. The rationale for this recommendation is to
provide routine and structure for the client, helping to
promote a move away from chaotic and risky behaviour.
Supervision of the consumption of medicines used in the
treatment of people with mental illness can in a similar way
help to reduce chaotic and risky behaviour. Regular contact
with the pharmacist and pharmacy staff can help to reduce
the social isolation felt by many people with mental illness.
Pharmacists and their staff are well placed to spot the
deterioration of a person’s mental state and alert other
members of the healthcare team to the person’s need for
further support if appropriate.
Tuberculosis is becoming an increasing problem in many
parts of the country, especially among socially
disadvantaged groups such as the homeless. The effective
treatment of tuberculosis and the prevention of acquired
drug resistance relies on full compliance with medication
treatment regimens. Directly observed therapy schemes
(DOTS) have been used in many countries to improve
compliance. A comparison of self treatment versus various
forms of DOT has shown that completion of treatment is
significantly higher when the treatment is supervised.3
An example claim/audit form and “three-way” agreement
form are provided with this service specification, which
could be adopted locally by PCOs.
Background information for Drug Action Team (DAT)
commissioners: 
Service Specification Tier (2 or 3), Pharmaceutical Services
for Drug Users, 
National Treatment Agency for Substance Misuse, 2005,
www.nta.nhs.uk
CPPE training which may support this service:
Opiate treatment: Supporting pharmacists for improved
patient care open learning
Public health – drug users, harm reduction workshop
Mental health workshop series
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essential services. If this is not the case for a particular medicine which may be included in the service, local arrangements will need to be
developed.
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10  Appendix 5: NHS community
pharmacy contractual framework
enhanced service – supplementary
prescribing by pharmacists
1 Service description
1.1 The service is based on a voluntary partnership
between an independent prescriber (doctor or dentist)
and a supplementary prescriber, to implement an
agreed patient specific clinical management plan
(CMP) with the patient’s agreement. The
supplementary prescriber will need to be able to
access patients’ medical records.
1.2 The supplementary prescriber will support the patient
in managing their condition, including ordering of
diagnostic tests, monitoring test results and response
to treatment and adjusting treatment accordingly. The
supplementary prescriber will also refer to other
primary care professionals where appropriate.
2 Aims and intended service outcomes
3.1 Maximising patient and NHS benefit in relation to
quicker and more efficient access to medicines.
• Improving choice, convenience and access to
treatment.
• Improve quality of service to patients without
compromising patient safety.
• Make better use of the skills of pharmacists.
• Contribute to the introduction of more flexible team
working across the NHS.
• Provide support and advice, including referral to the
GP and other healthcare professionals when
appropriate.
• Increase the involvement of the patient in treatment
decisions.
• Improve primary care capacity by reducing medical
practice workload.
3 Service outline
3.1 Prior to commissioning this service the following
issues must be considered:
• patient safety
• how to maximise patient and NHS benefits
• local NHS need
• ability of the supplementary prescriber to prescribe in
their post immediately following training
• access to a budget and prescription pads
• access to patient records
• access to a designated medical practitioner during
training, recognised by the commissioning
organisation as (i) having the experience in the relevant
field of practice, (ii) training and experience in
supervision, support and assessment of trainees, and
(iii) who has agreed to provide the student with
opportunities to develop competencies in prescribing,
and to supervise, support and assess the student
during their clinical placement
• access to CPD opportunities and ideally a mentor (not
necessarily the independent prescriber)
3.2 The pharmacist has at least two years post-
registration experience and has successfully
completed an accredited supplementary prescribing
training course and is registered with the RPSGB as a
supplementary prescriber.
3.3 A doctor/dentist has been identified and agreed to
take on the role of independent prescriber.
3.4 Eligibility criteria and referral protocols are agreed
locally with the PCO and doctor and should be in line
with DH guidance (supplementary prescribing by
nurses, pharmacists, chiropodists/podiatrists,
physiotherapists and radiographers within the NHS in
England, A guide for implementation).
3.5 The location used for the provision of the service
provides privacy and safety and appropriate facilities
for examination of patients, for example hand washing
facilities. The facilities should comply with good
infection control practice.
3.6 Protocols and audit for quality assurance of any eq-
uipment used are in place.
3.7 For each new patient identified for the service an
individual clinical management plan is agreed between
the independent prescriber, supplementary prescriber
and patient. The CMP should include:
• the name of the patient
• the illness or conditions which may be treated by the
supplementary prescriber
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3 Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public
Health Tuberculosis Guidelines Panel. JAMA 1998; 279: 943-948
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• the date on which the plan takes effect and when it is
to be reviewed by the independent prescriber
• a reference to the class or description of medicines 
or types of appliances which may be prescribed or
administered, following any local formularies which 
are in place
• any restrictions or limitations on the strength or doses
of medicines
• length of treatment if applicable
• relevant warning about the patients sensitivities to
medicines
• arrangements for notification of important adverse
drug reactions; and
• the circumstances in which the supplementary
prescriber should refer to or seek the advice of the
independent prescriber.
3.8 The CMP should be kept as simple as possible and
where national guidelines already exist (e.g. BTS
Guidelines for Asthma) these could be referred to
within the CMP.
3.9 Supplementary prescribers should have the ability to
request a range of tests from the local pathology
laboratory, as described in the CMP.
3.10 Pharmacist supplementary prescribers should make
contemporaneous records of all their interventions 
in the common patient record. If however this is not
possible a separate record should be made which
should be transferred to the common patient record
as soon as possible. Only in exceptional
circumstances, (e.g. a weekend or public holiday),
should this period exceed 48 hours from the writing 
of the prescription.
3.11 For each patient the pharmacist should where
appropriate:
• carry out a medication review
• perform or request any testing that may be required
• monitor the patient for response to treatment
• assess the results of any testing carried out
• adjust medicines dosages accordingly (within CMP),
• discuss the treatment options with the patient
• prescribe,
• update the patient record, and
• communicate with the independent prescriber
appropriately.
3.12 Patients would normally be seen within the community
pharmacy or GP surgery; however domiciliary visits
may be appropriate in some circumstances.
3.13 The PCO will need to provide a framework for the
recording of relevant service information for the
purposes of audit and the claiming of payment.
3.14 The PCO will need to provide details of relevant
referral points which pharmacy staff can use to
signpost service users who require further assistance.
4 Suggested quality indicators
4.1 The pharmacy reviews its standard operating
procedures and the referral pathways for the service
on an annual basis.
4.2 The pharmacy can demonstrate that pharmacist
supplementary prescribers involved in the provision 
of the service have undertaken CPD relevant to 
this service.
4.3 The pharmacy can show that prescribing by the
supplementary prescriber is in accordance with CMPs.
4.4 The pharmacy can demonstrate robust quality
assurance for any processes or equipment used.
4.5 The pharmacy participates in an annual PCO
organised audit of service provision.
4.6 The pharmacy co-operates with any locally agreed
PCO-led assessment of service user experience.
Background information – not part of the service
specification
Supplementary prescribing by nurses, pharmacists,
chiropodists/podiatrists, physiotherapists and radiographers





Amended POM order – SI 2003 No. 699 The NHS
(Amendments relating to prescribing by nurses and
pharmacists etc.) (England) Regulations 2003
(http://www.opsi.gov.uk/si/si2003/20030699.htm)
CPPE training which may support this service:
Medicines management workshop series
Prescribing support open learning series
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11 Appendix 6: Abbreviations
BBV Blood-borne virus
CPPE Centre for Pharmacy Postgraduate
Education (University of Manchester)
DAT Drug action team
DIP Drugs Intervention Programme
GPwSI General practitioner with special
interest
HBV Hepatitis B virus
LPC Local pharmaceutical committee
MoC Models of care 2002 and Models of
care: Update 2005 – produced by the
National Treatment Agency for
Substance Misuse
NHS National Health Service
NPA National Pharmacy Association
NTA National Treatment Agency for
Substance Misuse
www.nta.nhs.uk (England only)
PSNC Pharmaceutical Services Negotiating
Committee www.psnc.org.uk (England
and Wales)
PCO Primary care organisation
PCT Primary care trust
PhwSI Pharmacist with special interest
RCGP Royal College of General Practitioners
RPSGB Royal Pharmaceutical Society of Great
Britain 
SOP Standard operating procedure
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12  Further information
For further information, contact:
• Marion Walker, pharmacist, Clinical Team, National
Treatment Agency
• Your NTA regional manager
Our thanks go to the Royal Pharmaceutical Society’s
substance misuse group, chaired by Sue Kilby, for their 
help in compiling this document and in particular to:
Kay Roberts FRPharmS , 
Sadia Khan MRPharmS, RPSGB
Alastair Buxton MRPharmS and Barbara Parsons
MRPharmS, PSNC.
In addition our thanks go to:
Paul Brookes, Annette Dale-Perera and Emily Finch,
National Treatment Agency, for their help in producing 
this document
We are grateful for the additional comment and advice
provided by Colin Bradbury, Jonathon Buisson, 
Julie Daneshyar, Barry Eveleigh, Mark Galloway, 
Mark Harris, Vanessa Hayward, Gillian Hawksworth, 
Duncan Jenkins, Hugo Luck, Andrea Nunney,
Graham Parsons, Lisa Stanway, David Skidmore, 
Vanessa Taylor and Debbie Woolley.
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